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Zusammenfassung 
In biotechnologischen Verfahren, einschließlich der Affinitätseparation und der Analyse, 
werden hoch selektive und affine Liganden benötigt. Aufgrund ihrer 
Bindungseigenschaften ermöglichen Aptamere die Aufreinigung und Detektion sowohl 
von Proteinen, als auch von kleinen Molekülen. Die herkömmlichen Methoden zur 
affinitätsbasierten Proteinaufreinigung verwenden überwiegend Antikörper als Liganden. 
Eine sehr konkurrenzfähige Alternative stellt die Anwendung von aptamermodifizierten 
Partikeln dar. Aptamere sind einzelsträngige DNA- oder RNA-Oligonukleotide, die in der 
Lage sind, verschiedene Arten von Molekülen zu binden. Verglichen mit Antikörpern 
verfügen Aptamere zwar über ähnliche Spezifitäten und Affinitäten, weisen aber eine 
höhere Stabilität auf. 
Der Hauptteil der vorliegenden Arbeit untersucht das Potential und die Effektivität von 
Aptameren hinsichtlich der Reinigung von Proteinen und kleinen Molekülen. Für die 
Untersuchungen wurden his-getaggte Proteine, Antikörper und kleine Moleküle 
(Theophyllin, Malathion) verwendet. Zur Entwicklung der Aufreinigungsstrategien wurden 
Magnetpartikel als festes Trägermaterial für die Immobilisierung der Aptamer genutzt. 
Ausgehend von einem bereits bestehenden Protokoll wurde die Reinigung his-getaggter 
Proteine über aptamermodifizierte Magnetpartikel optimiert. Nach der Optimierung wurde 
das Protokoll erfolgreich auf weitere Aptamere, die gegen humane Antikörper, 
Theophyllin und Malathion gerichtet sind, übertragen und angepasst. Um eine 
maßstabsgetreue Vergrößerung der entwickelten Aufreinigungsstrategien zu ermöglichen, 
wurde die Methode zudem auf weitere chromatographische Trägermaterialien übertragen. 
Aptamermodifizierte Sepharose und CIM
®
 DISK wurden erfolgreich zur Reinigung des 
humanen Fc Fragments eingesetzt. Um humanes IgG aufzureinigen wurde das Aptamer 
zusätzlich mit einem integrierten Spacer versehen und auf Sepharose immobilisiert. 
Ein weiterer Teil dieser Arbeit dient der Entwicklung von neuen Methoden zur 
Proteindetektion unter Verwendung aptamermodifizierter Quantenpunkte. Die 
Nachweistauglichkeit von Aptameren wurde durch den Einsatz von aptamermodifizierten 
Quantenpunkten mit der Reverse Phase Protein Microarray Methode untersucht. Dieses 
Experiment zeigte eine hohe Spezifität der Aptamere. 
Key words: Aptamer, affinitätsbasierte Separation, Aufreinigung, Oberflächen 
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Abstract 
High selective and affine ligands are required in biotechnological techniques, including 
affinity separation and analysis. Because of their binding properties, aptamers can be used 
to purify and detect proteins, as well as small molecules. The conventional methods for 
affinity-based purification of proteins use primarily antibodies. A strongly competitive 
alternative is the application of aptamer-modified particles. Aptamers are single stranded 
DNA- or RNA- oligonucleotides that are able to bind different kinds of molecules. 
Compared with antibodies, aptamers exhibit similar specificities and affinities, but higher 
stability. 
The main part of this work intends to examine the capability and effectiveness of aptamers 
to purify proteins and small molecules. His-tagged proteins, antibodies and small 
molecules (theophylline, malathion) were employed for the testing. Magnetic beads were 
used as solid support for the immobilization of aptamers during the development of the 
purification strategies. 
Based on an existing protocol, the purification of his-tagged proteins via aptamer-modified 
magnetic beads was optimized. After optimization, the protocol was successfully 
transferred and adapted to other aptamers directed against human antibodies, theophylline 
and malathion. In order to enable a scale-up of the developed purification strategy, the 
method was transferred to other chromatographic supports. Aptamer-modified sepharose 
and CIM
®
 DISK were successfully used to purify human Fc fragment. In order to purify 
human IgG, aptamer with integrated spacer was employed and immobilized on sepharose.  
Another part of this work provides the development of new methods for the detection of 
proteins by using aptamer-modified quantum dots. The applicability of aptamers for 
detection of proteins was examined by using lab-made aptamer-modified quantum dots in a 
reverse phase protein microarray. This experiment exhibited high specificities of aptamers. 
Key words: aptamer, affinity separation, purification, surfaces 
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1 Introduction and Task 
The efforts to look for new methods or to improve already-known methods to purify and 
detect proteins in biotechnological and analytical applications have never ceased. Because 
each cell is composed of a complex mixture of proteins in different compositions, it is 
difficult to purify an individual protein. However, the variation of sizes, charges and 
solubilities or affinities toward binding partners make it possible that proteins can be 
purified in different ways. Conventional methods for protein purification are for example 
gel filtration (GF), ion exchange choromatography (IEX), hydrophobic interaction 
chromatography (HIC) and affinity chromatography (AC). Based on these conventional 
methods, the application of different kinds of aptamer-modified particles becomes a 
strongly competitive alternative. In this context, aptamer-based high selective and specific 
affinity separations are advantageous. Aptamers are single stranded DNA or RNA 
oligonucleotides that are able to bind different kinds of molecules. Compared with 
previously developed affinity chromatography methods that are primarily based on 
antibodies, aptamers exhibit although similar specificities and affinities to their targets, yet 
higher stability to higher temperature and extreme pH values. Especially, they enable the 
purification of targets under mild conditions and can be denatured and renatured, which 
enables regeneration of aptamer-modified supports. Furthermore, aptamers can be selected 
in vitro via various SELEX (Systematic Evolution of Ligands by Exponential enrichment) 
processes based on their specificity and affinity recognition and binding properties with 
their targets. Once a new aptamer is selected, it is easy to be chemical synthesized, which 
reduces the cost of production. 
Besides their applications in the downstream processes, aptamers can also be used to detect 
proteins. In order to detect proteins, the development of indirect optical methods is very 
important, for example for the staining of proteins. Fluorescence labelling is one of the 
most widely used methods for protein detection. Compared with normally used organic 
fluorophores or reporter proteins such as GFP (green fluorescent protein), the use of 
quantum dots, fluorescent semiconductor nanoparticles, in combination with aptamers, is a 
promising alternative to current methods. Due to the stability and modifiability of the 
quantum dots, as well as the quick and easy identification of aptamers against a variety of 
proteins, the application of aptamer-modified quantum dots will be investigated in this 
thesis. 
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The main part of this work intends to examine the capability and effectiveness of aptamers 
to purify proteins and small molecules. Three solid supports will be used for the aptamer 
immobilization: magnetic beads, sepharose and CIM
®
 DISK (CIM
®
 monolithic columns). 
His-tagged proteins [Pseudomonas Fluorescens Esterase I (PFEI), human leukocyte 
antigen (HLA)], antibodies [Fc fragment, human Immunoglobulin G (IgG)] and small 
active substances (theophyllin, malathion) are employed for the testing of aptamer 
functionalities. The study should conduct through a series of experiments with each next 
one performed based on the success of the previous one. Aptamer-modified magnetic 
beads against his-tagged protein PFEI will be first examined, followed by his-tagged 
protein HLA, antibodies (Fc fragment of human IgG, IgGs), and small molecules 
(theophylline and malathion). As the aptamer-based purification is till now solely realized 
in rather small-scale, the scale-up for future preparative scale will be done via aptamer-
modified sepharose and CIM
®
 monolithic columns. Finally, conventional chromatography 
methods, like the commonly used purification by using immobilized metal chelate affinity 
chromatography (IMAC) for his-tagged proteins and protein A for antibodies will be tested 
and compared with the developed aptamer-based methods. The second part of this work 
deals with the utilization of aptamers for the detection of their targets. Thereby lab-made 
aptamer-modified quantum dots (QD) will be examined in a reverse phase microarray.  
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2 Theory 
Aptamers are short, stable single-stranded DNA or RNA oligonucleotides or peptide 
molecules that can bind with high affinity and specificity to different types of targets [1]. 
The word aptamer is derived from Latin aptus (= fitting) and Greek meros (= part). Natural 
aptamers exist in riboswitches [2]. Aptamers that consist of single-stranded DNA- or 
RNA- strands with a length of 25 to 80 nucleotides were classified as DNA or RNA 
aptamers. Aptamers that consist of amino acids and can interact with other protein inside 
cells were peptide aptamers [3, 4]. A lot of aptamers can bind to their targets with Kd 
(dissociation constant) in the range of 1 pM to 1 nM [5-7]. They can bind to metal ions [8, 
9], vitamins [10], drugs [11-13], proteins [14, 15], nucleic acids [16-18], small organic 
compounds: for example organic dyes [19, 20], and even entire organisms like viruses [21, 
22] and cells [23-26]. How aptamers recognize and interact with their targets depends on 
the nature of targets, the nucleotide sequences and three dimensional structures of the 
aptamers. Those tRNA, ribozymes, DNA binding proteins and DNAzymes are examples of 
how nucleic acids recognize proteins via molecular shape [27-31]. Aptamers can be 
selected in vitro. This in vitro selection technique is named as Systematic Evolution of 
Ligands by Exponential enrichment (SELEX) [1, 4, 32, 33]. With the SELEX method, 
aptamers are enriched from large pools of partially randomized oligonucleotides containing 
approximately 10
15
 different sequences. The selection process is initiated by incubation of 
the oligonucleotides with a target which is either coupled to a matrix (e.g., magnetic beads) 
[25, 34-39] or on a surface (e.g., cell surface) [40-45]. Subsequently, non-binding 
oligonucleotide molecules are washed away, and the bound molecules are recovered, 
amplified by PCR (Polymerase Chain Reaction) or RT-PCR (Real Time-Polymerase Chain 
Reaction) [46, 47], and then separated into single-stranded oligonucleotides again. These 
oligonucleotides are subjected to a subsequent SELEX cycle. Typically, aptamers with 
high affinity will be obtained through 10 to 15 SELEX cycles of selection and 
amplification. Several variations of the SELEX procedure and other techniques have been 
developed and successfully applied over the past years [33, 48]. 
2.1 Origin of aptamer-technology 
The development of aptamer-technology could be traced back to the discovery of 
ribozymes. In 1989, Thomas Cech from University of Colorado and Sidney Altman from 
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Yale University were awarded with the Nobel Prize because they discovered that single-
stranded RNA-molecules exhibiting enzymatic properties existed in the nature. The finding 
reveals that RNAs are not only carriers that deliver genetic information from DNAs to 
proteins, but also catalysts in chemical reactions like enzymes [49-52]. Therefore, this 
catalytically active RNA strands were termed ribozymes. Before the discovery of 
ribozymes, it was a common understanding that only proteins could act as enzymes. When 
ribozymes bind to specific substrates, their catalytic properties are activated. Following the 
discovery of ribozymes, in 1990, three research groups independently reported RNA 
aptamers for the first time. The group of Ellington and Szostak identified RNA molecules 
binding to organic dyes by in vitro selection. They introduced the term aptamer [1]. 
Another group of Tuerk and Gold reported that in vitro-selected RNA molecules could 
bind to the T4 DNA polymerase from bacteriophage [4]. The group of Robertson and 
Joyce worked with ribozymes and found that ribozymes changed their functionalities 
during the in vitro selection, which lead to DNA degradation [53]. Two years later, 
Elington and Szostak discovered single-stranded DNAs, which showed higher stabilities 
than RNAs [54]. However, RNA aptamers can bind not only to the protein binding region, 
but in many cases to protein itself. Thus, RNA aptamers are capable to distinguish between 
various isoforms of a target. It seems that RNA aptamers are better suited to attach to a 
molecule, which is why many research groups still prefer to use RNA aptamers in their 
work although RNAs are not stable to nucleases [55], even thought production of RNAs is 
expensive. In the last ten years, a variety of targets were tested to investigate aptamers´ 
binding capacity [56-62].  
2.2 Structures of aptamers 
The recognition and binding of molecules (targets) by aptamers are mainly based on the 
special aptamers´ three-dimensional structures [63]. They have two features: secondary 
and tertiary elements [64-67]. The secondary structures consist of hydrogen bonds between 
the complementary nucleotide bases and are influenced by the aptamers´ nucleotide 
sequences [68]. Known forms of secondary structures include, for example, loops, 
mismatches or junctions (Figure 2.2 1) [69-73], and pseudoknots (Figure 2.2 2) [73, 74]. A 
pseudoknot is formed when bases outside of the stem-loop bind with bases within the loop, 
which in return forms a second stem-loop (Figure 2.2 2) [73]. 
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Figure 2.2 1: Different secondary structures of aptamers (A) stem-loop, (B) mismatch, (C) three-way 
junction [73]. 
 
 
 
Figure 2.2 2: Schematic representation of the formation of a pseudoknot [73]. 
The complex tertiary structures are formed by interactions of existing secondary structure 
elements [69, 73]. Tinocco et al. (1999) observed that during the formation of tertiary 
structures, the secondary elements will normally not changed, however, the stability of 
some area will decreased. For example, kissing-hairpins will be influenced and changed. 
The secondary and tertiary oligonucleotide structures can be stabilized through the 
interactions between various metal ions and the negatively charged sugar-phosphate 
backbone of the nucleotide [69, 70, 75-77]. For example, the reformation and stabilization 
of kissing-haripins structures can be carried out via addition of magnesium ions. The 
secondary structures are “pre-folded”, they exist without the presence of metal ions, and 
the structures will not change in the presence of metal ions. In contrast, in some cases, 
tertiary structures are folded only in the presence of metal ions [69, 78]. Furthermore, 
monovalent ions such as K
+
 and Na
+
 promote the formation and stabilization of G-
quadruplex structures [79]. The G-quadruplexes consist of four-stranded inter- or intra-
molecular structures, consisting of a square arrangement guanine. G-quadruplexes can 
occur when aptamers have a high proportion of guanine [80]. One advantage of metal ion-
dependent structure formation is the possibility of a simple regeneration of the aptamer. By 
removal of the ions, for example divalent cations, with chelating reagents such as 
ethylenediaminetetraacetic acid (EDTA), the target molecule will be released from the 
aptamer. To investigate the possibilities of aptamer folding, an aptamer structure prediction 
is helpful. However, depending on the external conditions, for instance, buffer, temperature, 
ionic concentrations, pH-values, etc., various aptamer structures can coexit in equilibrium 
[69].  
15 
 
2.3 Binding mechanisms of aptamers 
Through intra-molecular hybridization, aptamers can fold into particular molecular shapes. 
By various structural shapes, aptamers can recognize and bind their targets through 
hydrogen bonds, hydrophobic and electrostatic interactions, as well as van der Waals force, 
steric influence by aromatic stacking or, in most cases, a combination thereof [81]. In the 
simplest case of aptamer-target binding, aptamers have already folded correctly into their 
three dimensional structure in the absence of the target, and the target attaches to the pre-
folded aptamer according to the "key-lock principle" (key-lock mechanism). However, 
aptamers form the final structures in most cases during the binding process. This binding 
mechanism is called induced-fit mechanism [82]. Induced-fit mechanism could be 
confirmed by various investigation methods for most known aptamer-target complexes: for 
instance, x-ray diffraction and NMR spectroscopy [69, 83-85]. Aptamer against 
theophylline gives a good example of induced-fit mechanism. As soon as the theophylline 
approaches to the aptamer, two internal-loop regions were formed. But in the presence of 
other methylxanthines (for example, caffeine, theobromine), which have similar structure 
like theophylline, corresponding aptamer 3D (three dimensional) structure is not formed 
[86].  
Based on the classical key-lock and induced-fit mechanisms, more binding forms between 
aptamers and targets are conceivable. For example, RNA aptamer-protein-complexes were 
built through induced-fit from both sides [87-89]. In addition to the aptamer structure 
change, structures of proteins can also be changed during the binding to form a stable 
complex [87]. In conclusion, aptamers have different binding mechanisms, therefore the 
binding mechanism for each aptamer-target complex should be considered independently.  
In most instances, binding domains of aptamers play an important role in the target binding. 
But in some cases the non-binding domains may interfere with the interaction between the 
aptamer and target and eventually prevent the binding domain from folding into the desired 
3D conformation [90]. This may result in reduction or complete loss of the aptamer 
binding affinity. In order to stabilize the correct binding conformation of the aptamer, 
monovalent cations such as Na
+
 and K
+
 can be used as well as divalent ions such as Mg
2+
, 
and Ca
2+
. In some thrombin aptasensor studies, the effects of these cations were validated 
by addition of Na
+
 or K
+
 which could stabilize G-quadruplex structures and reduce 
nonspecific binding [91, 92]. However, Na
+
 or K
+
is also able to interact with negatively 
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charged phosphate backbone of an aptamer and result in weak complexes at a higher cation 
concentration [92]. Thus, they may lead to the conformational changes of binding site and 
lessen the affinity of aptamers to their targets. Under such circumstances, suitable cation 
concentrations have to be used during binding, so that aptamers can bind their targets 
properly. Nevertherless, aptamers binding to their targets are generally performed in the 
buffer used during the selection of aptamers. 
2.4 Selection of aptamers 
The SELEX process was discovered by Tuerk [4] und Gold [1] independently at the 
beginning of 1990. This method is based on the specific recognition and binding of 
oligonucleotides to target molecules and enables the extraction of the most appropriate 
aptamer sequences against a variety of different molecules [93]. The conventional SELEX 
process and two variations of SELEX are presented below. 
2.4.1 Conventional SELEX procedure 
The steps of the conventional SELEX procedure are shown in figure 2.4 1. The target 
molecule is immobilized on a solid phase, usually an affinity column based on agarose or 
sepharose [1, 94]. The immobilized targets are incubated with a highly diverse 
oligonucleotide library (pool). The initially used oligonucleotide library consists of a 
multitude of different DNA or RNA sequences, which are produced entirely by chemical 
synthesis [95, 96]. The wide variety of DNA or RNA pools ensures that each individual, 
synthesized oligonucleotide molecule has a unique sequence. In practice, the diversity of 
sequences is limited from 10
14
 to 10
15
 [90, 97-99]. Those sequences which have no or only 
a small affinity to the target molecule are removed through several washing steps. The 
stronger binding sequences are then eluted, amplified by PCR and then the smaller pool of 
binders is introduced to another SELEX cycle. This procedure is repeated until there are 
only very strong binding sequences left in the oligonucleotide pool. Usually it takes about 
ten to fifteen cycles [90]. Afterwards, these acquired sequences are amplified and 
sequenced. Hereafter, the binding properties of these sequences are investigated with the 
help of target molecules. The duration of the entire process including the final cloning with 
sequencing is approximately two months [90]. Once the aptamer sequence is known, it can 
be produced relatively easily and cheap with chemical solid-phase synthesis. 
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Figure 2.4 1: Schema of the in vitro SELEX process to obtain aptamers [100]. 
The SELEX process can be adjusted by selective variation to reach desired sequence with 
specific properties. For instance aptamers can be obtained with greatly increased 
specificity in a counter-SELEX. This specificity allows aptamers to distinguish very 
similar structures, such as enantiomers [101, 102]. 
2.4.2 MonoLEX  
The MonoLEX procedure is a one-step selection process for the recovery of aptamer 
sequences by a single affinity chromatography step. The process starts with the incubation 
of the library with the target molecule, which is immobilized on an affinity column. 
Subsequently the non-binding sequences are removed by excessive washing steps. After 
subsequent physical segmentation of the affinity column, bound aptamers are removed via 
heat denaturation from the column slices. Finally, eluted aptamers are amplified via a 
single final PCR amplification step [103]. The aptamers against human Fc fragment, which 
were used in this study, were derived from a MonoLEX-process by the company AptaRes 
(Mittenwalde, Germany). 
2.4.3 FluMag-SELEX  
The FluMag-SELEX process differs from the conventional selection methods by the use of 
fluorescent dyes for the nucleic acid quantification [33, 104]. In this method, the target is 
coupled to magnetic particles (magnetic beads). Magnetic beads show several advantages. 
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First, they require few targets. Second, they enable automation. Third, the magnetic 
separation works fast, which increases the efficiency of the entire process. By fluorescent 
labeling of the bound aptamers after the first selection-cycle, the depletion of the non-
binding oligonucleotides, and also the enrichment of target-specific aptamers can be 
monitored during the SELEX procedure. Upon completion of the selection process, the 
oligonucleotides can be synthesized without fluorescent dyes for further analysis and use. 
2.5 Advantages of aptamers over antibodies 
Although antibodies are able to bind their targets remarkably, aptamers show advantages in 
multiple aspects. First, the production of aptamers with in vitro selection is better than the 
production of antibodies with in vivo process, because the in vivo selection can only be 
done under physiological conditions. This restricts the application and function of 
antibodies. On the contrary, aptamers can be optimized under any conditions. Furthermore, 
under an in vitro process, the control over the production is very high. An investigator can 
recover aptamers that bind to a particular region of the target under specific binding 
conditions, such as salt concentration, pH-value and temperature. Second, the variation 
batches can be minimized. By isolation aptamers in vitro, an aptamer can be produced for 
any target molecule and can be synthesized rapidly, while each immunoassay must be 
optimized during each production by isolation antibodies in vivo. Third, given the fact that, 
the selection of antibody could last as long as 6 months, aptamers can be obtained in 
approximately two months. Fourth, the production of antibodies involves an immune 
response, while aptamers can be isolated by in vitro methods without immune response. 
Therefore, aptamers can be selected to recognize and bind a wide range of targets 
including toxic compounds and inherently non-immounogenic molecules that antibodies 
are hard to be raised against.  Fifth, aptamers are more chemically stable over a wide range 
of temperature. They can be regenerated easily after denaturation. Their ability to renature 
from a denatured state provides very long shelf life. Sixth, aptamers are easy to be 
modified and labeled. Site-specific modification techniques are capable to attach various 
molecules such as biotin groups [105], thiol groups [106], and label molecules [107] at 3′ 
or 5′ end of aptamer without affecting the target binding site and can make one-to-one 
conjugate (aptamer to label) [108-110]. However, labels on antibodies can cause them to 
lose their affinity to their target molecules, because the labels occur at a random position of 
antibodies. Finally, as aptamers are 10-100 times smaller than antibodies, they are 
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expected to achieve higher immobilization density [90]. Table 2.5 1 shows the comparison 
of aptamers and antibodies [93, 111-113]. 
Table 2.5 1: Comparison of aptamers and antibodies as recognition molecules. 
Field Antibody Aptamer 
production 
in vivo (animals or cell lines) 
limited in selection conditions  
in vitro 
various selection parameters applicable  
batch-to-batch 
variation 
due to variations in the production, 
each immunoassay must be optimized 
production via chemical synthesis, 
reproducible with little variations 
selection period more than 6 months approximately two months 
target 
production against little immunogenic 
or toxic targets is very difficult 
production is independent of the 
immunogenicity and toxicity targets 
stability risk of irreversible denaturation reversible denaturation 
modification can not be modified during production can be modified during production 
labeling 
occurs at a random position, lead to 
reduction or loss of binding affinity 
can be defined to a desired position 
without affecting the binding affinity 
2.6 Applications of aptamers 
Because of relatively high stability and easy production, aptamers have received more and 
more attention within life science research and applications. Aptamers are playing their 
roles in ELISAs (enzyme-linked immuno sorbent assay) [114, 115], western blots [116], 
flow cytometry [117, 118] and microarrays [119-122] and may replace antibodies in all of 
the areas currently dominated by antibodies. Aptamers are also used in medical area for 
diagnosis, treatment of diseases and development of medications because of their low or 
non-immunogenic properties [100, 123, 124]. Similarly, as aptamers can be chemically 
modified, the pharmacokinetics can be improved through specific chemical modifications 
[100, 125]. Aptamers are recently reported in the application of aptasensors for detection 
of various substances, such as bio-molecules or toxins [126, 127]. A new interesting 
application is the purification of proteins [128]. For example, recombinant Ig-fusion 
protein with an L-selectin-tag was successfully purified from the supernatant of eukaryotic 
cell cultivations by using an aptamer affinity chromatography in 1999 [129].  
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2.7 Application of aptamers in affinity separations 
As antibodies´ competitors, aptamers have already successfully been used in the following 
applications: liquid chromatography (LC), capillary electro chromatography (CEC) [130], 
high-pressure liquid chromatography (HPLC) [131] and magnetic separations [36]. The 
core of all these applications is affinity separation (referred to review [132]). 
2.7.1 Separations of small molecules via specific aptamer-target-recognition 
In the approach of liquid chromatography, adenosine was successfully separated from 
related compounds like NAD (nicotinamide adenine dinucleotide), AMP (adenosine 
monophosphate), ADP (adenosine diphosphate) and ATP (adenosine triphosphate) via 
isocratic elution [133] by utilizing different affinities towards the aptamer. It was also 
reported that adenosine was successfully separated from complex biological samples via 
aptamer-modified solid matrix and mobile phase [134, 135]. An example of separation by 
utilizing capillary electro chromatography was reported by Clark et al. (2003). RNA 
aptamers against flavin mononucleotide (FMN) were immobilized on capillaries. The 
FMN could be separated from other molecules, which have no flavin moiety [136-138]. 
This experiment specifically showed the high stability of aptamers against organic solvents 
by using 50% acetonitrile [139]. In a striking example of specificity, aptamers against the 
theophylline (1, 3-dimethylxanthine) bind with 10,000-fold lower affinity to caffeine 
(1,3,7-trimethylxanthine) that differs from theophylline only by a single methyl group [48]. 
2.7.2 Separations of small molecules via enantioselective properties of aptamers  
As aptamers are able to distinguish very similar structures, such as enantiomers, they have 
been successfully used to separate the enantiomers of adenosine [140] and arginine-
vasopressin (AVP) [131]. Michaud et al. (2004) reported in his research that DNA 
aptamers could be selected against D-adenosine and L- tyrosine amide for the separation of 
respective enantiomers. The results showed D-adenosine had an average enantiomer 
selectivity and L-tyrosine amide an excellent enantiomer selectivity [141]. Later, Brumbt 
et al. (2005) used a D-RNA aptamer instead of aforementioned DNA aptamers directed 
against L-arginine. Unfortunately, the RNA aptamer was degraded very quickly via 
RNases. Although only natural D-oligonucleotides will be accepted as substrats by 
nucleases, it is not difficult to overcome the limitation of degradation. The L-RNA aptamer 
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which is the mirror image of the natural D-RNA aptamer was created. Thus the L-RNA 
against the mirror image of targets can replace the original D-RNA aptamer against the 
targets [55].  
2.7.3 Separations of small molecules via non-specific aptamer-target-recognition 
Separation can not only be performed with the target-specific recognition, but also via non-
target-specific aptamers. Some small molecules like aromatic hydrocarbons can be 
separated via non-target-specific aptamers which contain G-quartets and related 
oligonucleotides. For example, DNA aptamers selected against thrombin can be used to 
separate benzoperylene and naphthalene [142]. Another example for separation of isomeric 
dipeptides by utilizing G-quadruplexes was reported by Charles et al. (2002) [143]. 
Moreover, G-quadruplexes have also been used for the separation of homodipeptides and 
alanyl dipeptides [144], fibrinogen peptides [145] and binary mixtures of amino acids 
[142]. Vo et al. (2006) acclaimed that some instable G-quartet structures are beneficial for 
the non-target-specific binding [145]. 
2.7.4 Separations of proteins via specific aptamer-target-recognition 
A four-plane G-quartet DNA aptamer against bovine beta-lactoglobulin gives an example 
for target-specific separation of proteins. This DNA aptamer separated the variants A and 
B of lactoglobulin, although variants A and B differed only by 2 of their 162 amino acid 
residues [139]. Using the same method, via DNA oligonucleotides with G-quartet 
structures, alpha-, beta-, kappa-casein, alpha-lactoalbumin and beta-lactogobulin from 
bovine milk proteins were successfully separated [146]. 
The application of aptamer-based protein purification was first discovered by Roming et al. 
(1999). A 36nt biotinylated DNA aptamer was immobilized on streptavidin-modified resin. 
As the aptamer recognized and bound to the lectin domain of human L-selectin, 
recombinant human L-selectin-Ig fusion protein with the extracellular lectin domain was 
successfully purified from a CHO (chinese hamster ovary) cell culture supernatants [129]. 
Moreover, Connor et al. (2006) used a DNA aptamer directed against thrombin to purify 
the target protein from human serum albumin. The target protein was eluted by DNAse 
[147]. With the same elution strategy, thyroid transcription factor 1 (TTF1) from complex 
proteinmixtures and bacterial lysates was purified utilizing aptamer [128]. Another 
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example reported by Oktem et al. (2007), DNA aptamers directed against thermus 
aquaticus DNA polymerase was immobilized on magnetic beads and were used to purify 
the target from bacterial lysates with a total of 93% purity and 89% recovery. This 
experiment was performed in a one-step purification procedure [39].  
Recently, the use of DNA aptamers for the purification of his-tagged proteins was 
discovered [36]. Aptamers which were directed against his-tagged proteins were first 
immobilized on magnetic beads and then incubated with corresponding his-tagged proteins 
from crude E. coli lysates. With the help of 1M imidazole, the purified his-tagged proteins 
could be eluted. The effectiveness of purification is similar to the immobilized metal 
chelate chromatography [36]. 
In 2008, Miyakawa et al. reported to use RNA aptamers to purify IgG. An RNA aptamer 
was first selected directed against the Fc fragment of human IgG, and then used to purify 
IgG from serum. It was demonstrated that the optimized 23-nucleotide RNA aptamer 
bound only to the Fc fragment of human IgG, not to other species of IgGs, this is because 
that the 3D conformation of the recognition sites on the Fc domain differ significantly 
among different species of IgGs. Therefore, the high specificity of the aptamer can be used 
as a protein A alternative for affinity purification of human IgG. Compared to purification 
of IgG from CHO culture fluid with protein A, aptamer-based purification showed similar 
efficiencies [148].  
Furthermore, aptamers can distinguish between closely related but non-identical members 
of a protein family, or between different functional or conformational states of the same 
protein. The separation of his-tagged proteins from E. coli lysates [36] and the separation 
of human IgG from the human sera, CHO culture fluid [148, 149] with the help of aptamer 
were referred for the aptamer-based downstream process in this study.  
2.7.5 Separations of proteins via non-specific aptamer-target-recognition 
In addition to non-target-specific aptamers´ applications of separating small molecules, the 
G-quartets of aptamers can separate proteins as well. Several applications of aptamers in 
this field have been reported. Zhao et al. (2008) reported a successful purification of target 
protein from human serum and rat liver tissue lysate via DNA aptamers immobilized on a 
monolithic support. The DNA aptamer was selected directed against cytochrome C [150]. 
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This monolithic support immobilized aptamer was also used for the purification of 
thrombin. The reason why this aptamer can be applied to both target molecules is that their 
G-quartet structure showed affinity to both targets [151]. Another example showed a G-
quartet aptamer which was originally selected against thrombin was used to separate 
various species of albumins [152]. Since these non-target-specific separations are based on 
weak and non-specific interactions, their application is limited. Separation based on high 
affinity and specificity has a broader prospect [153]. 
2.8 Application of aptamers in downstream processes 
Because aptamers exhibit high affinity and selectivity towards their corresponding targets, 
they can therefore act as affinity ligands for the binding and purification of corresponding 
targets. Based on current applications of aptamers in affinity separations described above, 
aptamer-based purifications are investigated in this study. The strategy of aptamer 
application in the downstream process will be divided as followings: (i) immobilization of 
aptamers, (ii) binding of aptamers with their targets, (iii) eluting of targets from aptamer-
modified matrixs, (iv) regeneration and storage of aptamer-modified matrixs (referred to 
review [132]). 
2.8.1 Immobilization of aptamers 
In the downstream process, aptamers should be first immobilized on solid supports. As 
aptamers show a size range of approximately 13-26 kDa, it is possible that they are able to 
be immobilized in a higher density than antibodies, which are around 150 kDa. The high 
aptamer density on the solid support enhances the efficiency of support´s utilization. 
Theoretically higher aptamer density can bind more targets. However, this could only work 
for small targets, because large targets require more space for themselves.  
In order to immobilize selected aptamers on designated supports, generally noncovalent 
attachment or covalent immobilization is applied. A typical example of noncovalent 
binding is the attachment of biotinylated aptamers onto streptavidin coated 
chromatographic supports. The easy conduction of this immobilization procedure makes it 
a popular choice [55, 128, 129, 131, 133, 154-156]. However, this noncolvalent binding 
method shows limitations in comparison of covalent binding. The noncovalent binding 
between biothinylated aptamers and streptavidin depends on the ionic strength. Under a 
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low ionic strength condition, the aptamer-streptavidin-complex can undergo dissociation. 
For example, approximately 25% of bound aptamers are released from streptavidin at 30
o
C 
with a low ionic strength [157]. As streptavidin can undergo irreversible denaturation, 
which will result in a loss of aptamer and thus the binding capacity, the purification 
conditions are largely restricted for aptamers which immobilized via biotin-streptavidin 
interaction. 
For most of the downstream processes, covalent binding between aptamers and supports is 
very important, because the covalent binding is stable, which can prevent the release of 
aptamers during the later elution of targets and thus facilitate the later regeneration of 
aptamer-modified supports. To achieve covalent immobilization, the previously selected 
aptamers and the surface of solid supports should be first chemically modified. Aptamer 
modificated with functional groups can be easily done at desired position during their in 
vitro synthesis.  
2.8.2 Binding of aptamers with their targets 
The effectiveness of aptamers binding with their corresponding targets is determined by 
their specific three dimensional structures, aptamers are able to fold into their 3D structures 
either in the presence of the target or in the selection buffer without target. The factors, for 
example buffer composition, pH-value and temperature that affect the aptamers´ correct 
folding must be carefully controlled in order to reach a good binding result. Usually, the 
buffer will be chosen for the binding of targets, which was used during the selection of the 
aptamer. Reported in multiple references is that a buffer composition can be modified and 
optimized as needed [140, 158]. A uniform buffer can also be chosen for different 
aptamers, which were selected in different buffers [159]. Even though choices for buffers 
are available, a few aptamers show dependence on the buffers containing cations, in which 
they could fold into their 3D conformation properly. It is known that cations like Mg
2+
 and 
Ca
2+
 are able to interact with negatively charged phosphate backbone of the aptamer, 
which improves the correct 3D folding of aptamers [130]. In addition to the buffer 
composition, the pH-value is also very important for the binding between aptamers and 
their targets because pH-variations may result in ionization. If the functional groups of the 
target, which directly interact with the aptamer´s binding site, are protonated or 
deprotonated through the change of pH-values, the binding between targets and aptamers 
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will be interrupted. The same is true, if the bases of aptamers which are responsible for 
binding of the target are protonated or deprotonated, aptamer´s folding will be interfered. 
Beside the buffer compositions and pH-value influences, temperature also plays an 
important role in the optimal binding of target. In general speaking, lower temperature 
results in higher affinity of aptamers to targets [130]. 
2.8.3 Eluting of targets from aptamer-modified matrixs 
Since binding can be achieved through aptamer´s 3D conformation, to recover the bound 
targets could be done by destroying the 3D conformation in the way to change buffer 
composition, pH-values, or temperature.  
As many aptamers´ correct folding rely on divalent ions, removing such divalent ions in 
the elution buffer and adding chelating ageints can make aptamers no longer able to fold 
into their 3D structures and therefore release the bound targets. For example, adding 
EDTA to the elution buffer can chelate divalent ions to form a metal-EDTA chelate and 
destroy the 3D conformations of such divalent ions dependent aptamers.  
Romig et al., reported that a L-selectin fusion protein was eluted from an aptamer-modified 
sepharose support via EDTA [129]. In addition to using EDTA, competitive molecules can 
be used for elution of the target. Since metal ions like Zn
2+
 and Ni
2+
 can coordinate to 
adenosine through N1 and N7, which can interfere with the binding between adenosine and 
aptamer, they were used as competitors for target elution [134]. It was reported recently, 
that imidazole could be utilized for the elution of his-tagged proteins from aptamer-
modified magnetic beads [36].  
Targets can also be eluted via changing the pH-value or heating the aptamer-target 
complex during elution steps. However, these methods only work for small molecules, not 
for proteins. Because most proteins denature under extreme pH values or degrade in 
heating.    
The target can also be eluted by removal aptamers from the solid support. It was reported 
that an aptamer against hepatitis C virus (HCV) RNA polymerase was immobilized via a 
photo-cleavable Fmoc linker. Results of this experiment showed that the aptamer and the 
bound target were both eluted under the irradiation with UV [160, 161]. This method is not 
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suitable for efficient purification of proteins, because the purified proteins are 
contaminated with aptamers after elution. Furthermore, the aptamer-modified solid support 
is destroyed after single-use. For the same reason, the elution of targets utilizing nucleases 
destroys the immobilized aptamers [128]. However, this approach can be used in analytical 
applications. 
Other elution-strategies are for example the utilization of detergents or urea, because they 
are able to destruct the correct folding of aptamers or targets. However, their 
incompatibility with the solid support or with the native state of the target limits the usage.  
2.8.4 Regeneration and storage of aptamer-modified matrixs 
Aptamers can be denaturated and renaturated. The regeneration process is relatively easy. 
It is known that heating can melt the secondary structures of aptamers, which can be used 
for denaturation. Usually, the aptamer renaturation can be performed by incubation of 
aptamer-modified support in the aptamer selection buffer. It was known RNA aptamers are 
not stable against nucleases, which results in a short-term stability and decreases the 
reusability of aptamer-modified supports. It was reported that the binding capacity for the 
target L-arginine was reduced to 65% in 8 days via enzymatic cleavage when using an 
RNA aptamer as an affinity ligand [55]. To avoid loss of binding capacity by enzymatic 
cleavage, nuclease resistant aptamers can be used, such as post-SELEX-modified aptamers 
[102]. Mirror images of the initial aptamer can be used for chiral separations to prevent 
aptamer degradation. Furthermore, DNA aptamers can also be successfully used for the 
purification of a target from a complex biological samples [36]. These DNA aptamers were 
immobilized on magnetic beads and displayed several successful protein purification and 
regeneration cycles [36]. It is also proved that DNA aptamer-modified magnetic beads can 
be stored in buffer at 4
o
C for up to 6 months [36]. Under various conditions, the stability of 
aptamer-modified columns can be improved. For example, an aptamer-modified column 
can be stored for several days in a solution of water and methanol (50%) with no influence 
on aptamer binding [140]. 
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2.8.5 Current limitations and future prospects for aptamer-based downstream 
processes 
The above sections revealed that several aptamers were successfully used in affinity 
separations. However, most of these aptamers which are suitable in affinity separations 
may not be available for the downstream process. This is because most aptamers were 
selected directed against their targets solely based on their specificity and affinity without 
considering possible elution conditions during the SELEX process. Therefore, elution 
strategies not compatible with the targets´ native state were applied. For example, during 
SELEX process, heat denaturation was used for the elution of oligonucleotides from the 
targets. But in the downstream process, heating destroys targets which are sensible to high 
temperature, such as proteins. Thus, gentle denaturation methods need to be developed 
during the SELEX process which can consequently be used in the aptamer-based 
downstream process for temperature sensible targets. Several mild elution conditions will 
be investigated in the present work. By adding imidazole, his-tagged proteins can be eluted. 
Imidazole plays a role as competitive molecule in the elution process. Thereby heat-
induced denaturation will be avoided. For the purification of antibodies, the elution 
strategy will be performed via removing divalent ions in the elution buffer and adding 
chelating agents EDTA to destroy aptamers´ 3D conformation, so that antibodies can be 
gently eluted. In addition to these mild elution strategies for proteins, suitable elution 
methods for aptamer-based purifications of small molecules were also investigated. It was 
reported that aptamers against theophylline (1, 3-dimethylxanthine) binds with 10,000-fold 
lower affinity to caffeine (1,3,7-trimethylxanthine) that differs from theophylline only by a 
single methyl group [48]. In this thesis, several elution methods will be investigated to 
achieve the optimal thophylline elution efficiency. It was known that malathion is used as 
insecticide and acaricide. Because of it´s hazardous effects on human health and the 
ecosystems, in some cases, malathion is regarded as contamination. Therefore malathion 
was employed in this study as another small molecule for the investigation of aptamer-
based downstream process, which is hoped to fulfill the possibility of removing or 
depletion contaminations utilizing aptamer.  
Moreover, the reports published till now are only limited to laboratory-scale. In industrial 
applications, amounts of kilogram aptamers would be required. Aptamers are already used 
in the therapeutic field, for example, the first therapeutic application was approved for the 
treatment of age-related macular degeneration in 2004 [162]. The required large-scale 
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synthesis of oligonucleotides is especially accelerated by biopharmaceutical companies. 
Thus if aptamers can be produced in large-scale at low cost, aptamer-based downstream 
process will have more prospects in the near future. In this study, scale-up of aptamer-
based purification strategies will be investigated. Because sepharose is commonly used as 
stationary phase in downstream processing, it will be employed for scale-up experiments. 
Moreover, considering that CIM
®
 monolithic columns have big internal pores and the 
purification process by using CIM
®
 DISK can be automated via FPLC, it will be employed 
as another solid support for aptamer-based large scale downstream process. 
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3 Results and discussion 
Downstream process plays an important role in biotechnology. In this study aptamers were 
used to purify proteins and small molecules. The first part of this study conducted the 
purification of his-tagged Pseudomonas Flurescens Esterase I (PFEI) from E. coli via 
immobilized aptamers on various solid supports like magnetic particles and N-
Hydroxysuccinimide (NHS)-activated sepharose; generalized this purification method to 
another target protein, that is the aptamer 6H5-based purification of human leukocyte 
antigen (HLA) utilizing carboxyl-modified magnetic beads and NHS-activated sepharose; 
compared this aptamer-based method with the conventional purification method for his-
tagged proteins by using his-select nickel magnetic agarose beads. Furthermore, in order to 
transfer the manual operations to the automatic control, an automatic purification process 
by using KingFischer was introduced and tested. In the second part of this study, an 
investigation was made for the downstream process of human Fc fragment and the whole 
IgG via immobilized aptamers on carboxyl-modified magnetic beads, NHS-modified 
sepharose and methylcarboxyl-modified CIM
®
 DISK. Comparison was made between 
conventional purification method by utilizing protein A and aptamer-based method for 
antibodies. As the first two parts handle the purification of proteins, the third part of this 
study examines aptamer-based purification methods for small molecule targets like 
theophylline and malathion. The development of aptamer-modified purification strategies 
for small molecules may not only be useful for the purification of the respective targets, it 
may also provide new avenues to remove or deplete contaminations such as toxins. In 
addition to the application of purification, aptamers can also be used to detect proteins. In 
the last part of this study, aptamer-modified quantum dot 525 was tested for the 
applicability of protein detection. 
3.1 Aptamer-based purification of his-tagged proteins 
In a previous pubilication, anti-his-tag aptamers modified with amino linkers were first 
covalently immobilized on amino-modified magnetic beads and then incubated with his-
tagged protein PFEI. This approach allowed the elution of the bound target protein 
utilizing imidazole [36]. Because this method required toxic cyanuric chloride and PFEI 
could bind unspecifically to the amino-modified magnetic beads. A new immobilization 
method was seeked. Considering that 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimid 
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(EDC) is a water soluble carbodiimide, it is generally used as a carboxyl activating agent 
for the coupling of primary amines to yield aminde bonds and the resulting urea can be 
easily separated, an EDC-based immobilization strategy was developed by using carboxyl-
modified magnetic beads in this study. Then, the process of aptamer-based purification of 
his-tagged proteins was applied to another target protein HLA in order to demonstrate the 
general applicability. Sepharose was introduced as solid support for scale-up of aptamer-
based downstream process. 
The target protein PFEI was produced in E. coli and purified via membrane adsorber-based 
IMAC. Purified PFEI was used to characterize the aptamer-modified supports with regard 
to aptamers´ binding capacity to their targets. PFEI from crude E. coli lysates was used to 
investigate the purification efficiency by using aptamers. Another his-tagged protein HLA 
from cell culture media was used to test the general applicability of aptamer-based 
purification efficiency. 
3.1.1 Immobilization of aptamers on amino-modified magnetic beads 
A suitable solid support is required for the immobilization of aptamers. Solid supports 
should be coated with functional groups, which enable the covalent binding with amino-
modified aptamers. Magnetic particles coated with affinity ligands become an efficient, 
alternative tool for a quick and easy extraction of biomolecules. Therefore magnetic 
particles coated with amino groups and carboxyl groups were investigated in this study. As 
in the previous pubilication, amino-modified aptamers were successfully immobilized on 
amino-modified magnetic beads via toxic cyanuric chloride. This method was first tested 
as the cornerstone of aptamer immobilization. BioMag
® 
Amine magnetic beads consist of a 
suspension of magnetic iron oxide particles coated with primary amino groups, the amino 
groups allow covalent attachment of proteins or ligands with retention of biological 
activity.  
In order to immobilize aptamers directed against his-tag on amino-modified magnetic 
beads, amino-modified aptamer 6H7 was first activated via the agent: cyanuric chloride 
(Fig. 3.1.1 1). This immobilization allowed the oriented binding of the aptamers to achieve 
high functionality [36, 122].  
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Figure 3.1.1 1: Immobilization of amino-modified aptamers to amino-modified magnetic beads via 
cyanuric chloride. (A) The amino-modified aptamer is activated via cyanuric chloride. (B) The 
activated aptamer is immobilized on amino-modified magnetic beads. 
In order to investigate the functionalities of aptamers, which immobilized on amino-
modified magnetic beads, via IMAC purified PFEI was utilized. Functionalities of 
aptamers can be interpreted via two key parameters: aptamer activity and elution efficiency. 
The aptamer binding activity (AAPFEI) is defined as the percentage of the amount of bound 
PFEI divided by the amount of immobilized aptamer on the magnetic beads. The elution 
efficiency (EEPFEI) is the percentage of the amount of eluted PFEI divided by the amount 
of bound PFEI. Using purified PFEI enables the determination of the amount of bound and 
eluted PFEI. To realize the binding between immobilized aptamers and PFEI, the correct 
3D conformations of aptamers are crucial. Because aptamers can fold into their three 
dimentional structures correctly in the buffer, in which they were selected, before 
incubation PFEI with immobilizied aptamers, PFEI was first transferred to the slection 
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buffer of corresponding aptamers. After incubation, the unspecifically bound PFEI was 
washed down via wash buffer, to avoid losing PFEI activity in the elution process, mild 
elution condition was used. According to the previous study from Koekpinar et al. [36] 
Imidazole was added to release the bound PFEI with more ease because of the competition 
between imidazole and histidine. 
The amount of aptamer immobilized on the magnetic beads (DApt) was quantified as well 
as the amount of PFEI bound to the immobilized aptamer (QPFEI) and the amount of eluted 
PFEI (EPFEI). The amount of immobilized aptamer 6H7 was calculated based on the 
Lambert-Beer equation by an extinction coefficient of 382 mM
-1
cm
-1 
utilizing NanoDrop
TM
 
1000. The molecular weight of aptamer 6H7 is 12667 Da. The amount of bound and eluted 
PFEI was also calculated with the help of using NanoDrop
TM
 1000. Due to the presence of 
imidazole in protein elution solutions, the determination of the absorbance of eluted PFEI 
by using NanoDrop
TM
 1000 was disturbed. Therefore, dialysis was performed before the 
analysis to remove the contamination of imidazole from elution solutions of PFEI. Because 
some PFEI was losing during dialysis, another method of Bradford assay for the 
determination of the PFEI concentraions was carried out. Via Brandford assay, proteins 
could be detected colorimetrically via coomassie brilliant blue-staining. The increase of 
absorbance at 595 nm is the protein concentration in a solution. Bovine serum albumin 
(BSA) was used as reference in the concentration range of 0-200 µg/ml. [163]. Table 
3.1.1 1 and Figure 3.1.1 2 show the results of the functionalities from aptamer 6H7 
immobilized on amino-modified magnetic beads. Based on the pubilication from Kokpinar, 
that the amount of immobilized aptamer was saturated by applied aptamer concentration of 
1500 µg/ml and the amount of eluted PFEI was saturated by applied aptamer concentration 
of 1000 µg/ml [36], the highest concentration of applied aptamer was chosen at 85 µM in 
this experiment, which is in accordance with 1070 µg/ml for aptamer 6H5 and 1076 µg/ml 
for aptamer 6H7. Since the functionalities of the aptamer may be weakened at high 
immobilization densities due to steric hindrance, the aptamer loading density was 
optimized by variation of aptamer concentrations (0, 25, 45 and 85 µM) during the 
coupling procedure, which resulted in no, low, medium and high aptamer loading. 0 µM 
aptamer was chosen as a negative control, which performed as non-aptamer-modified 
amino-magnetic beads. 
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Table 3.1.1 1: Characterization of aptamer 6H7 functionalities utilizing purified PFEI 
c [µM]
a
 
DApt
 b
  
[pmol/mg beads] 
QPFEI 
c 
[pmol/mg beads] 
EPFEI 
d 
[pmol/mg beads] 
AAPFEI 
e 
[%] 
EEPFEI 
f 
[%] 
0   174 ± 7 69.4 ± 31   39.9 ± 48 
25 491 ± 23 264 ± 4 256.3 ± 7 42.0 ± 6 97.1 ± 4 
45 881 ± 25 259 ± 12 119.1 ± 5 29.4 ± 7 46.0 ± 9 
85 1584 ± 20 183 ± 8 45.4 ± 1 11.6 ± 6 24.8 ± 7 
a
 applied aptamer concentrations during immobilization, 
b
 aptamer loading densities on amino-
modified magnetic beads, 
c
 amount of bound PFEI (via IMAC purified) to immobilized aptamer, 
d
 
amount of eluted PFEI, 
e
 aptamer activity ratio for PFEI (QPFEI/DApt), 
f
 elution efficiency ratio for 
PFEI (EPFEI/QPFEI).  
Table 3.1.1 1 shows the amount of immobilized aptamer 6H7 on the amino-modified 
magnetic beads, the amount of bound PFEI to immobilized aptamer 6H7, the amount of 
eluted PFEI and the calculated aptamer activity and PFEI elution efficiency achieved with 
different aptamer concentrations (0, 25, 45 and 85 µM). The data in table 3.1.1 1 displays 
that the aptamer concentration of 25 µM produced the highest aptamer activity and the best 
elution efficiency of PFEI. The amount of immobilized aptamer 6H7, the amount of bound 
PFEI and the amount of eluted PFEI under different aptamer concentrations are shown in 
the following graph (Fig.3.1.1 2). 
 
Figure 3.1.1 2: Influence of different aptamer concentrations applied to amino-modified magnetic 
beads on the amount of immobilized aptamer 6H7, the amount of bound and eluted PFEI. 
Figure 3.1.1 2 shows that the amount of immobilized aptamers increased with the 
increment of applied aptamer concentration. The amount of bound and eluted PFEI 
reached maximum at aptamer concentration of 25 µM. At aptamer concentration of 0 µM, 
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which means that no aptamers were applied to the amino-modified magnetic beads, an 
unexpected result occurred: PFEI bound directly to amino-modified magnetic beads. In 
order to replicate the result, PFEI from crude E. coli lysates was incubated with amino-
modified magnetic beads without aptamer. Samples were applied to SDS PAGE gel (Fig. 
3.1.1 3). At the elution fraction 1 (5), there was a clear band emerged at ca. 30 kDa (PFEI 
molecular weight), which was deeper and thicker than the band of the last wash fraction (4) 
-- a proof that PFEI bound unspecifically to the amino-modified beads. Considering the 
isoelectric point (PI) of PFEI is 11.562 (calculated with an online calculating editor 
www.isoelectric.ovh.org/files/calculate.php, based on amino acid sequences of PFEI [164]), 
under this condition, PI > pH (7.5), PFEI act as cation. The explaination of a formed ionic 
interaction between PFEI and amino groups could be that the PFEI binding surface was 
negative charged and the beads binding site was positive charged which led to the binding 
of PFEI directly onto the amino-modified magnetic beads. 
 
Figure 3.1.1 3: Negative control, binding of PFEI (from E. coli lysate) directly on amino-modified 
magnetic beads without aptamer. Following samples were applied: (1) supernatant of PFEI (from E. 
coli lysate) after incubation with amino-modified magnetic beads, (2-4) washing fractions, and (5-6) 
eluates.   
To avoid the unspecific binding of PFEI directly onto the amino-modified magnetic beads, 
an EDC-based immobilization strategy was developed in this study. Capping was designed 
to transfer amino groups which coated on the magnetic beads to carboxyl groups. It was 
assumed that no ionic interaction between PFEI and carboxyl groups formed and thereby 
avoided the unspecific binding. To achieve the coupling between the capped beads and the 
amino-modified aptamers, EDC was used as coupling agent. Capped beads were first 
activated via EDC. This procedure will be discussed in the chapter 3.1.3. To modify the 
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amino-modified magnetic beads via capping shows a further advantage, that the using of 
toxic cyanuric chloride will be avoided. 
3.1.2 Capping of amino-modified magnetic beads 
Succinic anhydride was employed to cap the amino groups on the beads surface. The 
amino groups of the magnetic beads were converted to carboxyl groups with the help of 
dimethyl sulfoxide (DMSO) and bicarbonate. DMSO is a polar aprotic solvent that 
dissolves both polar and non-polar compounds and is miscible in a wide range of organic 
solvents as well as water. Utilizing DMSO in the capping procedure, reaction was 
promoted. Sodium bicarbonate was also added in the succinic anhydride solution to adjust 
the pH value, so that the amino groups on the beads surface could easily attach to the 
carbonyl groups of the succinic anhydride. Figure 3.1.2 1 shows the reaction of capping by 
using succinic anhydride. 
Beads NH2 +
OO
O
DMSO
NaHCO3
Beads
H
N
OH
O
O
amino-modified
magnetic beads
succinic 
anhydride
capping of amino-modified 
magnetic beads  
Figure 3.1.2 1: Reaction of amino-modified beads with succinic anhydride (capping). 
The results showed that after capping of the amino-modified magnetic beads, amino-
modified aptamer 6H7 was bound to the beads by using EDC. Comparatively, PFEI did not 
bind directly to the capped beads (data not shown). Capped beads, however, reduced the 
aptamer loading density on the surface, which resulted in low binding capacity to proteins. 
To explore alternative support materials, which perform the advantage of capped beads, 
but enhance aptamer loading capacities, the carboxyl-modified magnetic beads (BioMag
®
 
Carboxyl) were investigated for the aptamer-based downstream process.  
3.1.3 Immobilization of aptamers on carboxyl-modified magnetic beads 
It is mentioned above that EDC is generally used as a carboxyl activating agent for the 
coupling of primary amines. Moreover, EDC is often used in combination with N-
Hydroxysuccinimide (NHS) to increase the coupling efficiency by creating a more reactive 
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ester product. Based on this theory, two methods for the immobilization of amino-modified 
aptamers on the carboxyl-modified magnetic beads were tested: the two-step coating 
procedure using EDC and NHS and the one-step coating procedure by using EDC. (The 
two-step and the one-step couplings were performed according to the protocol for 
Dynabeads
®
 M-270 Carboxylic Acid with slight modifications.  
http://www.invitrogen.com/site/us/en/home/References/protocols/proteins-expression-
isolation-and-analysis/protein-isolation-protocol/m-270-carboxylic-acid.html#prot2). Via 
SDS PAGE (gel not shown) and calculation with the help of NanoDrop
TM 
1000 
spectrophotometer (data not shown), the two-step coating procedure showed poorer 
aptamer binding to carboxyl-modified magnetic beads than the one-step coating. 
Presumably the active ester was hydrolyzed before the primary amino groups of aptamers 
reached the active center of ester. The used two-step coating protocol needed to be 
modified during the aptamer immobilization. Thus the one-step coating procedure was 
used in the following experiments. In the one-step coating process, EDC was used as 
coupling agent. The EDC coupling chemistry is shown in Fig. 3.1.3 1. 
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Figure 3.1.3 1: Immobilization of amino-modified aptamers to carboxyl-modified magnetic beads via 
EDC. (A) The carboxyl-modified magnetic beads are activated via EDC. (B) The amino-modified 
aptamer is immobilized on EDC-activated magnetic beads. 
It was assumed that lower applied aptamer concentrations could reduce the aptamer 
loading density on the surface of solid supports, which resulting in low binding capacity to 
targets, and higher applied aptamer concentrations could interfere the aptamer folding 
capacity to their 3D conformation, which resulting in low aptamer activity. To optimize the 
performance of aptamer-modified carboxyl beads, different concentrations of aptamer 6H7 
(0, 25, 50, 100 µM) were applied to carboxyl-modified magnetic beads during the EDC-
mediated coupling. 0 µM aptamer was chosen as a negative control. Via IMAC purified 
PFEI was used to characterize the functionalities of aptamer-modified beads with regard to 
aptamer activity and elution efficiency. Results are listed out in table 3.1.3 1. 
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Table 3.1.3 1: Characterization of aptamer 6H7 functionalities utilizing purified PFEI 
c [µM]
a
 
DApt
 b
  
[pmol/mg beads] 
QPFEI 
c 
[pmol/mg beads] 
EPFEI 
d 
[pmol/mg beads] 
AAPFEI 
e 
[%] 
EEPFEI 
f 
[%] 
0  -0.04 ± 1 -0.6 ± 3     
25 298.8 ± 7 82.9 ± 3 79.4 ± 4 27.7 ± 6 95.8 ± 9 
50 429.5 ± 11 107.3 ± 4 45.8 ± 1 25.0 ± 6 42.7 ± 6 
100 1166 ± 8 71.4 ± 7 27.5 ± 1 6.1 ± 10 38.5 ± 13 
a
 applied aptamer concentrations during immobilization, 
b
 aptamer loading densities on carboxyl-
modified magnetic beads, 
c
 amount of bound PFEI (via IMAC purified) to immobilized aptamer, 
d
 
amount of eluted PFEI, 
e
 aptamer activity ratio for PFEI (QPFEI/DApt), 
f
 elution efficiency ratio for 
PFEI (EPFEI/QPFEI). 
Table 3.1.3 1 shows the amount of immobilized aptamer 6H7 on the carboxyl-modified 
magnetic beads, the amount of bound PFEI to immobilized aptamer 6H7, the amount of 
eluted PFEI, the calculated aptamer binding activity and PFEI elution efficiency under 
different concentrations of aptamer 6H7 (0, 25, 50 and 100 µM) applied during the EDC-
based aptamer immobilization. At aptamer concentration of 25 µM, the highest aptamer 
binding activity and elution efficiency were reached. The highest aptamer binding activity, 
however, was only approximatly 28%. This could be caused by the high Kd value of the 
anti-his-tag aptamer. The aptamer binding activities went down with the increase of 
immobilized aptamer, these rather low aptamer binding activities may also be a result of 
steric hindrance due to too high dense immobilization. This finding supports the 
assumption that increase of aptamer density decrease of aptamer binding activity. Figure 
3.1.3 2 graphed the influence of different aptamer concentrations applied to carboxyl-
modified magnetic beads on the amount of immobilized aptamer 6H7, the amount of 
bound and eluted PFEI. 
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Figure 3.1.3 2: Influence of different aptamer concentrations applied to carboxyl-modified magnetic 
beads on the amount of immobilized aptamer 6H7, the amount of bound PFEI and eluted PFEI. 
In Figure 3.1.3 2, the amount of immobilized aptamers went up with the increase of 
applied aptamer concentrations. The amount of bound PFEI reached a maximum at 
aptamer concentration of 50 µM. However, the most eluted PFEI was reached at aptamer 
concentraion of 25 µM. The highest amount of bound PFEI at aptamer concentration of 
50 µM could be explained due to the higher aptamer immobilization density. However, at 
very high aptamer concentration (100 µM), due to extremely reduced aptamer binding 
activity, aptamers are no longer able to bind properly with their targets. The explaination of 
most eluted PFEI appeared at aptamer concentration of 25 µM is probably because 
imidazole can reach the aptamer binding site more easily under this aptamer-loading 
density on the surface of the supports. At aptamer concentration of 0 µM, there was no 
aptamer applied to carboxyl-modified beads, resulting in no bound and eluted PFEI. This 
absence of unspecific binding of PFEI to carboxyl-modified magnetic beads was 
confirmed by gel electrophoresis (Fig. 3.1.3 3). There was no bands emerged at 30 kDa in 
eluates (6 and 7), which clearly demonstrated that the binding of the target is based on the 
affinity of the aptamer. By using carboxyl-modified magnetic beads avoided the unspecific 
binding of PFEI when utilizing amino-modified beads and improved the poor aptamer 
loading density when using the capped beads. 
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Figure 3.1.3 3: Negative control, binding of PFEI (from E. coli lysate) directly on carboxyl-modified 
magnetic beads without aptamer. Following samples were applied: (M) molecular weight marker, (1) 
PFEI (from E. coli lysate) sample applied to carboxyl-modified magnetic beads, (2) supernatant of 
PFEI (from E. coli lysate) after incubation with carboxyl-modified magnetic beads, (3-5) washing 
fractions, and (6-7) eluates.   
3.1.3.1 Comparison of aptamer functionalities between aptamer 6H7 and 6H5 utilizing 
carboxyl-modified beads 
In order to find out the relation between aptamer types and their performance on the same 
carrier, aptamer 6H5 was tested and compared with aptamer 6H7. With the help of 
NanoDrop
TM
 spectrophotometer, the amount of immobilized aptamer 6H5 was calculated 
based on the Lambert-Beer equation by an extinction coefficient of 373 mM
-1
cm
-1
, while 
the extinction coefficient of aptamer 6H7 is 382 mM
-1
cm
-1
, as mentioned in the previous 
section. The molecular weight of aptamer 6H5 is 12598 Da. All determinations were 
analized for three times. The average values were used for the comparison. Three different 
concentrations (10, 25 and 40 µM) of each aptamer were investigated. The concentration 
of 10 µM was chosen in order to investigate the previous assumption of a decreased 
aptamer binding activity due to too high aptamer loading density when using an aptamer 
concentration of 25 µM. Carboxyl-modified magnetic beads were used as solid supports 
and via IMAC purified PFEI was used for the determination of aptamer functionalities. 
Results are listed out in table 3.1.3.1 1. 
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Table 3.1.3.1 1: Comparison of aptamer functionalities between aptamer 6H7 and 6H5 utilizing 
purified PFEI 
c [µM]
a
 
DApt
 b
  
[pmol/mg 
beads] 
QPFEI 
c 
[pmol/mg 
beads] 
EPFEI 
d 
[pmol/mg 
beads] 
AAPFEI 
e 
[%] 
EEPFEI 
f 
[%] 
Apt6H7(10µM) 157 ± 13 154.7 ± 1.4 46.6 ± 0.3 98.5 ± 9.2 30.2 ± 1.5 
Apt6H7(25µM) 501 ± 42 168.5 ± 1.5 163.7 ± 0.8 33.6 ± 9.2 97.1 ± 1.3 
Apt6H7(40µM) 1037 ± 39 213.7 ± 1.8 98.1 ± 0.1 20.6 ± 4.6 45.9 ± 0.9 
Apt6H5(10µM) 263 ± 32 244.2 ± 2 84.4 ± 0.2 92.9 ± 13 34.6 ± 1 
Apt6H5(25µM) 619 ± 29 276.1 ± 1.5 233.8 ± 0.4 44.6 ± 5.2 84.7 ± 0.7 
Apt6H5(40µM) 875 ± 27 358.4 ± 1.5 146.1 ± 0.3 40.9 ± 3.5 40.8 ± 0.6 
a
 applied aptamer concentrations during immobilization, 
b
 aptamer loading densities on carboxyl-
modified magnetic beads, 
c
 amount of bound PFEI (via IMAC purified) to immobilized aptamer, 
d
 
amount of eluted PFEI, 
e
 aptamer activity ratio for PFEI (QPFEI/DApt), 
f
 elution efficiency ratio for 
PFEI (EPFEI/QPFEI). 
Table 3.1.3.1 1 shows at aptamer concentration of 10 µM, the highest aptamer binding 
activities were reached. This confirms the finding that aptamer concentrations of 25 µM 
resulted in high immobilization densities that interfered with high aptamer activity. 
However, the elution efficiencies at aptamer concentration of 10 µM were very low. The 
low elution efficiencies were attributed to the unspecific bound PFEI among neighbouring 
immobilized aptamers. Although the amount of bound PFEI at aptamer concentration of 10 
µM was as high as at 25 µM, it seemed that the unspecific bound PFEI among 
neighbouring aptamers could neither be washed down entirely during the washing steps 
nor be eluted sufficiently during the elution steps. This effect occurred probably because of 
the low aptamer cover on the surface of supports, which enables the unspecific protein 
loading among neighboring aptamers. On the other hand, the highest PFEI elution 
efficiencies were achieved when using aptamer concentration of 25 µM. At this 
concentration, imidazole as competitor seemed to reach the aptamer binding site easily and 
released his-tagged protein PFEI very efficiently. The amount of immobilized aptamer 6H7 
and 6H5, the amount of bound and eluted PFEI are shown in Figure 3.1.3.1 1. 
42 
 
          A      
 
           B      
 
Figure 3.1.3.1 1: Comparison of aptamer functionalities between aptamer 6H7 and 6H5 on carboxyl-
modified magnetic beads. (A): aptamer 6H7 immobilized on carboxyl-modified magnetic beads; (B): 
aptamer 6H5 immobilized on carboxyl-modified magnetic beads. 
Figure 3.1.3.1 1 shows the functionalities of aptamer 6H7 and aptamer 6H5. Regarding to 
the immobilization tendency, aptamers 6H7 and 6H5 performed similar. For both types of 
aptamer, increasing of applied aptamer concentration increased the amount of immobilized 
aptamers on carboxyl-modified magnetic beads, which resulted in increased amount of 
bound PFEI. The amount of bound PFEI reached the peak at aptamer concentration of 40 
µM, while the largest amount of eluted PFEI was found at aptamer concentration of 25 µM. 
The reduced amount of eluted PFEI at aptamer concentration of 40 µM is probably 
because that imidazole could reach aptamer binding site difficultly under higher aptamer 
density. In this experiment, the highest aptamer activities were reached at aptamer 
concentration of 10 µM, with a value of over 90%, almost each aptamer binding PFEI and 
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folding into their 3D structures. But the aptamer cover on the surface was not saturated. 
The highest PFEI elution efficiency was achieved at aptamer concentration of 25 µM 
(Table 3.1.3.1 1). In conclusion, the aptamer concentration of 25 µM displayed the optimal 
results of PFEI purification by using carboxyl-modified magnetic beads. At this 
concentration, a resonable compromise between binding capacity of the aptamer-modified 
magnetic beads and the aptamer binding activity was found. The types of the aptamer (6H5 
versus 6H7) seemed to have a little impact on aptamer performance in this case. By using 
aptamer 6H5, the amount of bound and eluted PFEI was more than that by using aptamer 
6H7. To find out more information of the performance between aptamer 6H5 and 6H7, this 
experiment was repeated by using crude PFEI from E. coli lysate. Samples of aptamer 
6H5- and 6H7-based PFEI purification from E. coli lysate were analysed via SDS PAGE 
analysis (Figure 3.1.3.1 2). The applied concentrations of aptamer 6H5 and 6H7 were 25 
µM. Only slight difference was observed. More unspecific bound PFEI was found in the 
washing fractions by using 6H7 than 6H5. To summarize, aptamer 6H5 performed better 
than 6H7 in the purification of PFEI utilizing carboxyl-modified magnetic particles, which 
indicated higher binding affinity of aptamer 6H5 to targets when compared with aptamer 
6H7. 
 
Figure 3.1.3.1 2: Comparison of aptamer functionalities between aptamer 6H5 (left) and 6H7 (right) 
with concentration of 25 µM on carboxyl-modified magnetic beads. Following samples were applied: 
(M) molecular weight marker, (Lysate) PFEI (from E. coli lysate) sample applied to aptamer-modified 
magnetic beads, (DL) supernatant of PFEI (from E. coli lysate) after incubation with aptamer-
modified magnetic beads, (W3, W5) washing fractions, and (E1) eluate. 
3.1.3.2 Comparison of aptamer functionalities by using different types of beads 
Besides the carboxyl-modified magnetic particles mentioned above, taking into account, 
whether some other alternatives, which could be used as solid supports in the aptamer-
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based downstream processes and probably show more advantages when compared with 
carboxyl-modified magnetic beads? It was informed by purchasing that the maxi-carboxyl-
beads have more functional groups and higher binding capacity than the normal-carboxyl-
beads. Thus, maxi-carboxyl-beads were employed to compare with the normal-carboxyl-
beads, which were used in the aforementioned experiments. During the investigation, first, 
same aptamer 6H7s with concentration of 25 µM were immobilized on both of these 
carboxyl-modified beads. With the help of NanoDrop
TM
 1000 spectrophotometer, 
617.8 pmol aptamer per mg beads were found on the normal-carboxyl-beads and 
680.7 pmol aptamer per mg beads were detected on the maxi-carboxyl-beads. The 
difference was not significant, which could be attributed to the saturation of the aptamer. 
Therefore, aptamer 6H7s with concentration of 100 µM were tested and 871.9 pmol/mg 
beads aptamer were found on the normal-carboxyl-beads and 1036.3 pmol/mg beads 
aptamer on the maxi-carboxyl-beads. The results showed that maxi-carboxyl-beads were 
able to bind more aptamers. To further investigate the impact of beads type on aptamer 
purification efficiency, aptamer 6H7s with concentration of 100 µM and PFEI from E. coli 
lysate were used for the testing. Samples were examined via SDS PAGE analysis. No 
difference in purification was observed in the SDS PAGE gel (Fig. 3.1.3.2 1). It can be 
concluded that the types of beads did not affect the aptamer-based purification efficiency 
in the same beads concentration. In the following experiments, normal-carboxyl-beads 
were used further as solid supports. 
 
Figure 3.1.3.2 1: Comparison of aptamer functionalities between maxi-carboxyl-beads (left) and 
normal-carboxyl-beads (right) utilizing 100 µM aptamer 6H7. Following samples were applied: (1) 
PFEI (from E. coli lysate) sample applied to aptamer-modified magnetic beads, (2) supernatant of 
PFEI (from E. coli lysate) after incubation with aptamer-modified magnetic beads, (3–7) washing 
fractions, and (8-9) eluates. 
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3.1.4 Aptamer-based automatic purification utilizing a robot 
All previous experiments were performed manually. Automation is advantageous with 
regard on throughput as well as precision. The KingFisher device was chosen as a robot for 
the automatic purification process. First, the aptamer immobilization, protein binding and 
elution processes were programmed via corresponding KingFisher software. Afterwards, 
all samples with 100 µl (20 mg/ml carboxyl-modified magnetic beads, 25 µM aptamer 6H5 
solutions, 1 mg/ml PFEI from E. coli lysate, washing, elution, and aptamer selection 
buffers) were added into a 96 well plate, which was packed into the KingFisher device 
before the program was run. The same purification process in manual performance was 
conducted in automation. The results are displayed via SDS PAGE analysis (Fig. 3.1.4 1). 
 
Figure 3.1.4 1: Aptamer 6H5 (25 µM)-based PFEI automatic purification via KingFisher. Following 
samples were applied: (M) molecular weight marker, (Lysate) PFEI (from E. coli lysate) sample 
applied to aptamer-modified magnetic beads, (DL) supernatant of PFEI (from E. coli lysate) after 
incubation with aptamer-modified magnetic beads, (W3, W5 and W7) washing fractions, and (E1-E2) 
eluates. 
Even after 7 washing steps, PFEI was washed down from the aptamer-beads-matrix. These 
appearances could be suspected that the automatic operation was performed at room 
temperature and the binding between aptamer and target was impaired at higher 
temperature, which led to the releasing from binding partner. It was difficult to provide an 
opportunity to fulfil the automatic process at 4
o 
C, as the KingFisher robot must be 
controlled by computer, in which the corresponding software was installed. To test this 
hypothesis that aptamers and targets impaired due to room temperature, the same 
experiment was performed at 4
o 
C manually. The results are shown in Fig. 3.1.4 2.  
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Figure 3.1.4 2: Aptamer 6H5 (25 µM)-based PFEI manually purification at 4
o
C. Following samples 
were applied: (M) molecular weight marker, (Lysate) PFEI (from E. coli lysate) sample applied to 
aptamer-modified magnetic beads, (DL) supernatant of PFEI (from E. coli lysate) after incubation 
with aptamer-modified magnetic beads, (W1-W7) washing fractions, and (E1-E2) eluates. 
In the gel analysis, little PFEI released during the last washing step. The purity degree of 
both eluates was 100%, as determined by densitometry.  
To summarize, in order to enable the automated aptamer-based purification, KingFisher 
was introduced in this study for the aptamer-based PFEI purification utilizing carboxyl-
modified magnetic beads. The results were not as good as that by manual, as aptamers and 
targets impaired during the downstream process. It could be that the binding affinity 
between aptamers and PFEI is low in the room temperature. It is recommended that these 
experiments be run in the cooling chamber at 4
o
C in the further. 
3.1.5 Aptamer-based purification of his-tagged HLA utilizing carboxyl-modified 
magnetic beads 
PFEI was utilized as a model protein to determine the functionalities of immobilized 
aptamers directed against his-tag. In order to examine the general applicability of the 
developed purification strategy, his-tagged human leukocyte antigen (HLA) was used. 
HLA consists of a heavy chain (40 kDa) and a light chain (12 kDa). The aptamer 6H5-
based purification of HLA via carboxyl-modified magnetic beads was investigated. The 
purification process for HLA is generally the same as for PFEI. However, because HLA is 
relatively sensible to salt, salt was avoided in washing buffer. Thus, the selection buffer, 
which was used for aptamer selection was used as washing buffer. Similar to PFEI, before 
the incubation with immobilized aptamers, HLA was first transferred to the slection buffer. 
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Fig. 3.1.5 1 shows the SDS PAGE gel of the aptamer 6H5 (25 µM)-based HLA 
purification utilizing carboxyl-modified magnetic beads. 
 
Figure 3.1.5 1: Aptamer 6H5 (25 µM)-based HLA purification by using carboxyl-modified magnetic 
beads. Following samples were applied: (M) molecular weight marker, (HLA) HLA (from cell-culture 
supernatant) sample applied to aptamer-modified magnetic beads, (DL) supernatant of HLA (from 
cell-culture supernatant) after incubation with aptamer-modified magnetic beads, (W1–W5) washing 
fractions, and (E1-E2) eluates.  
In both eluates E1 and E2, two bands were discovered. At 40 kDa were heavy chains and 
over 10 kDa were light chains of HLA. With a little contamination at the very beginning of 
the running gel, the purity degree of the first eluate reached 85.2%, as determined by 
densitometry.   
3.1.6 Conventional IMAC-based downstream process by using his-select nickel 
magnetic agarose beads 
The aforementioned successful purification of his-tagged proteins utilizing aptamer-
modified magnetic beads confirmed the applicability of aptamers in the application of 
downstream processes. Because aptamers exhibit several advantages over conventional 
methods, comparative experimens between aptamer-based methods and conventional 
methods were considered and carried out. Conventionally, his-tagged proteins are purified 
via immobilized metal chelate affinity chromatography (IMAC). Here, the affinity of 
different transition metal ions towards histidine is exploited to purify the protein. The 
IMAC method shows disadvantages. First, a part of used metal ions from this nickel 
magnetic agarose beads are carcinogens [36]. Secondly, because the metal ions are 
complexed on the surface of material, the metal ligand could be leached from the column 
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during the purification process. This problem could be solved via the developed aptamer-
based downstream process. Since aptamers are covalently immobilized on the solid 
supports, they will not be leached during the purification procedure. To compare the 
purification obtained via aptamer-modified magnetic beads, his-select nickel magnetic 
agarose beads were used to purify PFEI from E. coli lysate. PFEI from lysate was first 
diluted in PBST-6H7 + 20 mM imidazole buffer to 1 mg/ml and then incubated with his-
select nickel agarose beads. Specific bound proteins were eluted with increased imidazole 
concentration of 250 mM. Different fractions of this separation were analyzed via SDS-
PAGE analysis (Fig. 3.1.6 1). The purity degree was 99%, as determined by densitometry. 
 
Figure 3.1.6 1: Purification of PFEI from E. coli lysate utilizing his-select nickel magnetic agarose 
beads (IMAC). Following samples were applied: (M) molecular weight marker, (lysate) PFEI (from E. 
coli lysate) sample applied to his-select nickel magnetic agarose beads, (DL) supernatant of PFEI (from 
E. coli lysate) after incubation with his-select nickel magnetic agarose beads, (W1-W3) washing 
fractions, and (E1) eluate.  
Compared with Fig. 3.1.4 2, in which the purity degree of PFEI by using aptamer 6H5 was 
100%, the purity degree of 99% utilizing IMAC method showed little difference. The 
similar purity degrees indicate that aptamer-based purification technology is a good 
alternative to conventional IMAC method. Taking into account, using aptamers in the 
downstream process for his-tagged proteins can overcome the disadvantages by using 
IMAC method. Therefore, aptamer-based downstream process shows great potential to 
replace the conventional method, especially in the biomedical applications. 
All experiments above showed that magnetic beads could be successfully used in the 
aptamer-based downstream process for his-tagged proteins. Although biomolecules can be 
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quickly and easily extracted via magnetic particles, it is very difficult to scal-up the 
aptamer-based downstream processes by using them, which limited the application in the 
industry in future. In order to provide a possibility to expand the production, some other 
materials were considerable for the immobilization of aptamers. Sepharose is commonly 
used in chromaographic separations of biomolecules. It is an excellent base matrix for high 
performance chromatographic procedures in different kinds of chromatographies and other 
modes of separation. Therefore NHS-activated sepharose 4 fast flow was chosen and tested 
as a further solid support.  
3.1.7 Scal-up via binding of aptamers on NHS-modified sepharose 
Amino-modified aptamers could bind directly on NHS-modified sepharose. The binding 
mechanism is shown in Fig. 3.1.7 1. Because NHS-functional groups lead to a self-signal, 
they disturb the measurement of aptamers´ absorbance at 260 nm, the absorbance of 
aptamers during the immobilization on sepharose could thereby not be determined via 
NanoDrop
TM
 1000. The analysis was then performed via developed propidium iodide (PI) 
assay. The performances of aptamers, which were immobilized on NHS-modified 
sepharose were investigated first utilizing via IMAC purified PFEI. The results are listed in 
table 3.1.7 1. 
Seph O
O
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O
O
Apt
NH2
C6-amino-modified aptamer
aptamer-modified sepharose
NHS-activated sepharose
+
Apt
H
N Seph
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Figure 3.1.7 1: Aptamer immobilization on the NHS-activated Sepharose 4 fast flow. 
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Table 3.1.7 1: Characterization of aptamer 6H5 functionalities immobilized on sepharose utilizing 
purified PFEI 
c [µM]
a
 
DApt
 b
  
[pmol/200 µl 
sepharose] 
QPFEI 
c 
[pmol/200 µl 
sepharose] 
EPFEI 
d 
[pmol/200µl 
sepharose] 
AAPFEI 
e 
[%] 
EEPFEI 
f 
[%] 
25  5130 ± 3 1385.2 ± 4 344.8 ± 2 27.0 ± 1 24.9 ± 1 
a
 applied aptamer concentration during immobilization, 
b
 aptamer loading density on NHS-modified 
sepharose, 
c
 amount of bound PFEI (via IMAC purified) to immobilized aptamer, 
d
 amount of eluted 
PFEI, 
e
 aptamer activity ratio for PFEI (QPFEI/DApt), 
f
 elution efficiency ratio for PFEI (EPFEI/QPFEI). 
Table 3.1.7 1 shows the amount of immobilized aptamer 6H5 (25 µM) on sepharose, the 
amount of bound PFEI on immobilized aptamer, the amount of eluted PFEI, the calculated 
aptamer binding activity and the PFEI elution efficiency. The low aptamer binding activity 
of only 27% was occured probably because sepharose is a pore material, aptamers 
immobilized within the sepharose pores were hindered in their optimal folding, which led 
to less specific binding of PFEI. The low PFEI elution efficiency might be caused by the 
PFEI diffusion in pores of sepharose. Longer elution time or more elution steps may be 
required to account for diffusion processes within the particles. To determine the 
purification efficiency, the same experiment was repeated by using PFEI from crude E. 
coli lysates. The SDS PAGE gel is shown in Fig. 3.1.7 2. The purity degree of the first 
eluate was 97.5%, as determined by densitometry. 
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Figure 3.1.7 2: Aptamer 6H5 (25 µM)-based PFEI (from E. coli lysate) purification by using NHS-
modified sepharose. Following samples were applied: (M) molecular weight marker, (Lysate) PFEI 
(from E. coli lysate) sample applied to aptamer-modified sepharose, (DL) supernatant of PFEI (from E. 
coli lysate) after incubation with aptamer-modified sepharose, (W1–W5) washing fractions, and (E1-
E2) eluates.  
In addition to PFEI, HLA was also tested for the aptamer-based scale-up downstream 
process. Due to HLA´s sensitivity to salt, washing was performed in the aptamer selection 
buffer. 
 
Figure 3.1.7 3: Aptamer 6H5 (25 µM)-based HLA (from cell-culture supernatant) purification by using 
NHS-modified sepharose. Following samples were applied: (M) molecular weight marker, (HLA) HLA 
(from cell-culture supernatant) sample applied to aptamer-modified sepharose, (DL) supernatant of 
HLA (from cell-culture supernatant) after incubation with aptamer-modified sepharose, (W1–W5) 
washing fractions, (E1-E3) eluates, and (Apt) aptamer 6H5 (25µM).  
Fig. 3.1.7 3 shows the gel of aptamer 6H5-based HLA purification utilizing NHS-activated 
sepharose. After two elution steps, there was still a lot of HLA bound to the immobilized 
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aptamer 6H5. The sepharose-aptamer-HLA complex was then incubated in Laemmli buffer. 
The sample was applied to the gel as third elution fraction. SDS PAGE analysis confirmed 
incomplete elution of HLA after two elution steps. It is presumable that sepharose is a 
porous media and diffusion processes within the material may require longer processing 
time. In the future, either the elution time needs to be extended or the elution steps need to 
be increased. In the elution fractions, HLA was detected with contaminations of BSA (see 
Fig. 3.1.7 3, by 66.5 kDa). Sample of applied aptamer 6H5 (25µM) was also applied in this 
gel to distinguish the light chain of HLA. It was displayed in gel, that the bands by 12 kDa 
were actually the HLA light chains. They are not bands of aptamers leached from the 
sepharose. The purity degree of the first elution fraction by utilizing sepharose was 74.1%, 
as determined by densitometry. 
To summarize, positive results were shown by aptamer-based his-tagged protein 
purifications. Different aptamers (6H5 and 6H7) were immobilized on different material 
(magnetic beads and sepharose) and successfully used for the purification of different his-
tagged proteins (PFEI and HLA). Furthermore, aptamer-based purification experiments 
resulted in similar purification efficiency to conventional his-select nickel agarose beads. 
Nevertheless, the developed purification strategies are only applicable to the isolation of 
his-tagged proteins. The next chapter of this thesis will describe the development of an 
aptamer-based purification of Fc fragment and human IgGs.  
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3.2 Aptamer-based purification of Fc fragment and IgGs 
Conventionally, protein A was used for the purification of antibodies. Aptamers were used 
in this study to test their applicability in the downstream processes for antibodies. In the 
purification of compounds that are used in pharmaceutical fields, aptamers show several 
advantages over protein A. First, Due to their in vitro production, contaminations with 
viruses are avoided. Thus, the production of aptamers in compliance with current good 
manufacturing practice is simplified. Secondly, aptamers have minimal propensity to elicit 
an antibody response [165]. This is especially advantageous in the downstream process of 
pharmaceutical antibodies, where the leakage of immunogenic protein A from the 
chromatographic device is a major concern necessary additional purification steps. Third, 
besides their lack of immunogenicity, aptamers that may have leaked from the column can 
be easily removed in the DNA removal step that is essential for the purification of 
pharmaceutical antibodies. Based on the non-immunogenicity of aptamers, their animal-
free and chemical synthesis, the developed aptamer-based downsteam processes are 
especially useful for the purification of pharmaceutical antibodies. 
DNA aptamers 264, 265 and 266 against Fc fragment and IgGs as well as aptamer 264 with 
integrated-spacer PEG6 against IgGs were used in this study. In a previous publication, it 
was reported that human IgG was successfully purified from cell culture supernatant via an 
RNA aptamer [148]. In contrast to the work from Miyakawa et al. [148], DNA aptamers, 
which selected from a MonoLex process for the purification of Fc fragment and IgG were 
investigated for the first time in this study. These selected DNA aptamers show two main 
advantages over RNA aptamers, that is, they are more stable and cheap. In order to 
generate divalent ions denpendent aptamers with 3D conformations, aptamers were 
selected in a buffer containing Mg
2+
 and Ca
2+
. This approach was chosen to enable the 
destruction of the 3D structures with chelating agents as a potential strategy for the mild 
elution of bound proteins. This mild elution condition described by Roming et al. [129] is 
contrary to the harsh acidic elution condition required for protein A-based purifications, 
which enables aptamer as strongly competitive alternative to protein A in the downstream 
process. 
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3.2.1 Immobilization of aptamers on magnetic beads 
According to the pubilished literature [36], an aptamer-based purification method for his-
tagged proteins utilizing amino-modified magnetic beads was tested in the aforementioned 
chapter of this work. It was introduced in chapter 3.1.1 that aptamer 6H7 was activated via 
cyanuric chloride and consequently immobilized onto amino-modified magnetic beads. 
This method was transferred to aptamers directed against human IgG as a cornerstone. A 
gentle elution process was developed and performed via adding 300 mM chelating agent 
EDTA to remove divalent ions and thereby destroy the aptamers´ 3D structure. The 
successful results of binding and elution of human IgG were demonstrated in Fig. 3.2.1 1A. 
This verified activities of immobilized aptamer and confirmed that the folding of aptamer´s 
3D structure depends on divalent ions. The possibility of regenerating aptamer-modified 
magnetic beads was also investigated. Regeneration of the aptamers could be achieved by 
washing and incubation with the selection buffer (Fig.3.2.1 2). After immobilization, the 
aptamer (blue) was folded into their three-dimensional structure by incubation them in the 
selection buffer including divalent ions. The target could be eluted by EDTA-induced 
unfolding of the aptamer. The aptamer-modified magnetic beads could be stored at 4 
o
C 
and then be used repeated for 3 times without losing aptamer functionalities. 
In complex IgG samples containing 10% fetal calf serum (FCS), unspecific binding of 
BSA to aptamer-modified magnetic beads was observed (Fig. 3.2.1 1B). Also observed 
was a rather low utilization of the applied aptamer. Only 19% of the applied aptamer were 
immobilized on the amino-modified particle surface when using 25 µM aptamer during the 
immobilization. This low efficiency may be attributed to either incomplete activation of 
the aptamer or by hydrolysis of the activated aptamer. It is also known, that amino-
modified surfaces may interact electrostatically with the phosphate backbone of aptamers 
which will result in misfolding and reduced binding activity of immobilized aptamer [122].  
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Figure 3.2.1 1: Binding studies utilizing pure human IgG (A) and human IgG supplemented with 10% 
1 mg/ml FCS (B). Following samples were applied: (1) molecular weight marker, (2) IgG samples 
applied to aptamer-modified amino magnetic beads, (3) supernatant of IgG samples after incubation 
with aptamer-modified amino magnetic beads, (4-6) washing fractions, and (7-8) eluates. 
 
Figure 3.2.1 2: Schematic regeneration of aptamer-modified magnetic beads. 
To overcome the limitations by using aptamers immobilized on amino-modified magnetic 
beads, an EDC-based immobilization strategy by using carboxyl-modified magnetic beads 
was used in the following researches. This developed method increased aptamer 
immobilization efficiency. Aptamer 264, 265, 266 were tested for the immobilization and 
binding with corresponding targets. Because aptamer 264 showed the best functionalities 
to their targets (data not shown), the following discussion only involves aptamer 264. 
3.2.2 Optimization of aptamer activity and binding capacity 
As aptamer binding activity ratio (AA) was defined as the the amount of bound protein 
divided by the amount of immobilized aptamers on the solid supports, it described the 
amount of appropriately immobilized aptamers that maintain binding property upon 
immobilization. It was found in the aforementioned chapter for aptamer-based purification 
of his-tagged protein that decreasing the amount of immobilized aptamer could provide 
more space for aptamers to fold correctly and thereby increase aptamer binding activity. 
On the other hand, a decrease of aptamer loading density may result in reduced binding 
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capacity because not enough aptamers exist to bind to their targets. It was also verified that 
higher amount of immobilized aptamer could reduce aptamer binding activity, because 
aptamers folding into their 3D structures might be interfered by steric or electrostatic 
hindrance due to neighboring aptamers. In order to achieve high binding activity of 
immobilized aptamers, as well as high binding capacity, the procedure was optimized with 
regard to the amount of immobilized aptamer. In this study, several different 
concentrations of aptamer 264 (0, 5, 10, 25, 50, 75, 100 µM) were tested during the 
immobilization (Fig. 3.2.2 1), 0 µM aptamer 264 was chosen as a negative control and 
100 µM was chosen as the amount of immobilized aptamer was presumably saturated 
under this concentration. 
Figure 3.2.2 1 shows that the amount of immobilized aptamer increased with increasing of 
applied concentration of aptamer until the level of 50 µM, where a maximum aptamer 
loading of approximately 1200 pmol/mg beads was reached.  
 
Figure 3.2.2 1: Aptamer loading on carboxyl-modified magnetic beads as a function of applied 
aptamer concentration during EDC coupling. 
To identify the optimal aptamer concentration for an optimal aptamer binding activity and 
binding capacity, pure commercial Fc fragment and IgG were incubated with aptamer-
modified magnetic beads respectively. The amount of immobilized aptamer on the 
magnetic beads (DApt) was quantified as well as the amount of bound and eluted Fc 
fragment (QFc and EFc) and the amount of bound and eluted IgG (QIgG and EIgG). The 
amount of immobilized aptamer 264 was calculated based on the Lambert–Beer equation 
by an extinction coefficient of 614 mM
-1
cm
-1
. The molecular weight of aptamer 264 is 
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19532 Da. Due to the presence of EDTA in eluate solutions, the determination of 
concentrations by using NanoDrop
TM
 1000 was disturbed. Therefore, the Bradford assay 
was used for the measurment of bound and eluted Fc fragment as well as IgG. The increase 
of absorbance at 595 nm corresponded to the protein concentration in a solution. Bovine 
serum albumin (BSA) was used as reference in the concentration range of 0-200 µg/ml. 
These values were used to calculate the aptamer binding activity ratio (AA) which was 
defined as the percentage of immobilized aptamer that has bound to target protein. Four 
different concentrations of aptamer 264 (0, 10, 25, 50 µM) resulting in no, low, medium 
and high aptamer loading were investigated. The aptamer concentration of 0 µM was used 
as a negative control, which performed as non-aptamer-modified carboxyl-magnetic beads. 
The results are shown in table 3.2.2 1 and table 3.2.2 2. 
Table 3.2.2 1: Characterization of aptamer functionalities for binding study with pure Fc fragment 
c [µM]
a
 
DApt
 b
  
[pmol/mg 
beads] 
QFc 
c 
[pmol/mg 
beads] 
EFc 
d 
[pmol/mg 
beads] 
AAFc 
e 
[%] 
EEFc 
f 
[%] 
 
0   219 ± 1 71 ± 7  32.3 ± 10 
10 387 ± 31 386 ± 4 324 ± 5 99.8 ± 9 84 ± 3 
25 780 ± 35 759 ± 3 698 ± 6 97.3 ± 5 92 ± 1 
50 1251 ± 20 683 ± 7 644 ± 8 54.6 ± 3 94.3 ± 2 
a
 applied aptamer concentrations during immobilization, 
b
 aptamer loading densities on carboxyl-
modified magnetic beads, 
c
 amount of bound Fc fragment to immobilized aptamer, 
d
 amount of eluted 
Fc fragment, 
e
 aptamer activity ratio for Fc fragment (QFc/DApt), 
f
 elution efficiency ratio for Fc 
fragment (EFc/QFc).  
Table 3.2.2 2: Characterization of aptamer functionalities for binding study with pure IgG 
c [µM]
a
 
DApt 
b 
[pmol/mg  
beads] 
QIgG 
c 
[pmol/mg  
beads] 
EIgG 
d 
[pmol/mg  
beads] 
AAIgG 
e 
[%] 
EEIgG 
f 
[%] 
 
0   347 ± 3 282.8 ± 4   81.6 ± 2 
10 329 ± 91 327 ± 1 326.9 ± 7 99.4 ± 28 99.9 ± 2 
25 758 ± 15 738 ± 2 681.9 ± 2 97.4  ± 2 92.4 ± 1 
50 1042 ± 103 727  ± 1 619.1 ± 4 69.8 ± 10 85.1 ± 1 
a
 applied aptamer concentrations during immobilization, 
b
 aptamer loading densities on carboxyl-
modified magnetic beads, 
c
 amount of bound IgG to immobilized aptamer, 
d
 amount of eluted IgG, 
e
 
aptamer activity ratio for IgG (QIgG/DApt), 
f
 elution efficiency ratio for IgG (EIgG/QIgG).  
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Table 3.2.2 1 shows the binding of Fc fragment. The aptamer binding activity reached the 
highest value of 99.8% at aptamer concentration of 10 µM. At aptamer concentration of 25 
µM, the aptamer binding activity was 97%. However, the amount of bound Fc fragment of 
386 pmol/mg beads at 10 µM was rather low. The aptamer concentration of 25 µM showed 
the most optimal results. At this concentration level, aptamer loading density was higher 
than that of 10 µM and thereby had sufficient binding capacity to the target protein. It 
resulted in the highest amount of bound Fc fragment with a value of 759 pmol/mg beads, 
which was almost twice as high as that at aptamer concentration of 10 µM. When the 
applied concentration level was increased to 50 µM, the highest aptamer loading density 
was reached. Nevertheless, the amount of bound Fc fragment was down to 683 pmol/mg 
beads and the aptamer binding activity reduced almost half. These results supported the 
hypothesis that a very high aptamer density could lead to steric or electrostatic hindrance 
and resulted in reduced aptamer binding activity and decreased binding capacity.  
The experiment was repeated with IgG. Table 3.2.2 2 shows the results of IgG binding 
study. Similar results were observed. Aptamer concentrations of 10 µM and 25 µM 
resulted in higher aptamer binding acitivities, ranging between 97% and 99%. An aptamer 
concentration of 50 µM resulted in reduced aptamer binding activity at level of only 69.8%. 
In conclusion, an aptamer concentration of 25 µM achieved the most optimal aptamer 
functionalities with approximately 750 pmol immobilized aptamers per mg beads.  
Besides aptamer binding activity ratio (AA), also the elution efficiency (EE) was 
determined since this value is relevant for the recovery of purified proteins. As expected, in 
the binding studies of Fc fragment and IgG respectively, the best elution efficiencies were 
also reached at aptamer concentration of 25 µM. Determined by Brandford assay, 
759 pmol Fc fragment were found to be bound to the immobilized aptamer 264 (25µM) and 
698 pmol Fc fragment were eluted, resulting in elution efficiency of 92% (Table 3.2.2 1). 
While 738 pmol IgG were found to be bound to the immobilized aptamer 264 (25µM) and 
682 pmol IgG were eluted, the elution efficiency reached 92.4% (Table 3.2.2 2). 
The results in table 3.2.2 1 and table 3.2.2 2 also revealed unspecific binding of Fc 
fragment and IgG to carboxyl-modified magnetic beads. The unspecific binding of IgG can 
be explained by its isoelectric point between 7 and 9.5 [166], which resulting in a positive 
net charge of IgG in SB (pH 7.3). Between the carboxyl-modified magnetic beads and IgG, 
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electrostatic attraction was formed. This ionic interaction led to the unspecific binding of 
IgG directly onto the carboxyl-modified magnetic beads. This explaination for the 
unspecific binding of IgG can be extended to the unspecific binding of Fc fragment. 
3.2.3 Aptamer-based purification of Fc fragment from FCS 
To test the aptamer-based purification efficiency for Fc fragment, 10% fetal calf serum 
(FCS) was added into pure commercial Fc fragment and this Fc fragment in FCS serum was 
incubated with aptamer 264-modified magnetic beads. Samples were analyzed via SDS-
PAGE analysis (Fig. 3.2.3 1). Within the three elution fractions, Fc fragment was found 
with minor contaminations of BSA. In the third elution fraction, aptamer 264 was found. 
This circumstance occured is probably because that the last elution step was performed 
over night in Laemmli buffer. Aptamers showed their unstable property when they were 
incubated over night in Laemmli buffer. The purity degree of the first eluate for Fc 
fragment was 82.9%, as determined by densitometry. 
 
Figure 3.2.3 1: SDS PAGE analysis of aptamer-based purification of Fc fragment from 10% FCS. 
Following samples were applied: (M) molecular weight marker, (Fc) FC (from 10% FCS) sample 
applied to aptamer-modified magnetic beads, (DL) supernatant of FC (from 10% FCS) after incubation 
with aptamer-modified magnetic beads, (W1-W5) washing fractions, and (E1-E3) eluates. 
3.2.4 Aptamer-based purification of human IgG from FCS 
In order to investigate the aptamer-based purification of IgG from complex samples, pure 
commercial IgG supplemented with 10% FCS was incubated with aptamer 264-modified 
magnetic beads and the process was analyzed via SDS-PAGE analysis (Fig. 3.2.4 1). 
Within the first elution fraction (Fig. 3.2.4 1, lane 6), IgG was found with minor 
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contaminations of BSA. The purity degree of IgG in the first elution fraction was 97%, as 
determined by densitometry. 
        
Figure 3.2.4 1: SDS PAGE analysis of aptamer-based purification of IgG from complex sample. 
Following samples were applied: (M) molecular weight marker, (1) IgG (from 10% FCS) sample 
applied to aptamer-modified magnetic beads, (2) supernatant of IgG (from 10% FCS) after incubation 
with aptamer-modified magnetic beads, (3-5) washing fractions, (6-7) eluates and (8) standard IgG.  
3.2.5 Conventional protein A-based downstream process 
BioMag
® 
Protein A was conventionally used for the purification of antibodies. The 
following experiments were conducted to compare the purification of antibodies with 
protein A and aptamer-based method. 
To test the protein A-based purification method, Fc fragment and IgG supplemented with 
10% FCS were used. In the eluates, purified Fc fragment was obtained with no visible 
contaminants (Fig. 3.2.5 1A), while IgG was purified with a little contamination of BSA 
(Fig. 3.2.5 1B). The purity degree of Fc fragment from 10% FCS in the first eluate was 
94.7%, while the purity degree of IgG from 10% FCS in the first eluate was 79.3%, as 
determined by densitometry. 
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         A                                             B 
    
Figure 3.2.5 1: (A) SDS PAGE analysis of protein A-based purification of Fc fragment from 10% FCS. 
Following samples were applied: (M) molecular weight marker, (FC+FCS) Fc fragment (from 10% 
FCS) sample applied to protein A, (DL) supernatant of Fc fragment (from 10% FCS) after incubation 
with protein A, (W1-W3) washing fractions, and (E1) eluate. (B) SDS PAGE analysis of protein A-
based purification of IgG from 10% FCS. Following samples were applied: (M) molecular weight 
marker, (IgG+FCS) IgG (from 10% FCS) sample applied to protein A, (DL) supernatant of IgG (from 
10% FCS) after incubation with protein A, (W1-W3) washing fractions, and (E1) eluate. 
The results of aptamer-based purification of Fc fragment and IgG from 10% FCS utilizing 
carboxyl-modified magnetic beads showed purity degree of 82.9% for Fc fragment and 
97% for IgG, similar to those from conventional protein A-based method. Moreover, 1 ml 
(5 mg) BioMag Protein A can bind approximately 0.2 mg IgG, while the calculated 
binding capacity of aptamer-based IgG purification showed a similar value of 0.25 mg per 
5 mg beads. However, aptamers are produced more easily, are more stable and require less 
harsh elution terms (e. g. 300 mM EDTA, pH 7.3). In contrast, protein A-based protein 
purification required harsher elution conditions (e. g. 100 mM glycine, pH 2.5). Under this 
harsher elution condition, the properties of purified IgG would be changed. Therefore, the 
aptamer-based purification process is a valuable and competitive alternative to protein A-
based purification of antibodies.   
3.2.6 Scale-up via binding of aptamers on NHS-modified sepharose and methyl-
carboxyl-modified CIM
® 
DISK 
Based on the successfully developed aptamer-based downstream processes utilizing 
carboxyl-modified magnetic beads, sepharose 4 fast flow was selected to enable an 
efficient scale-up of aptamer-based purification for Fc fragment and IgG. Concerning the 
62 
 
immobilization of aptamer 264 on NHS-activated sepharose, the binding mechanism was 
introduced in chapter 3.1.7 (Fig. 3.1.7 1). 
As a negative control, sepharose was treated in the same way as normal aptamer 
immobilization but without addition of aptamer during the immobilization procedure. The 
functionalities of aptamer-modified sepharose were first investigated by binding study with 
pure Fc fragment. SDS PAGE analysis showed that Fc fragment bound specifically to the 
immobilized aptamer (Fig. 3.2.6 1A), no binding occured for the negative control (Fig. 
3.2.6 1B). To judge the purification efficiency, the experiment was repeated with Fc 
fragment supplemented with 10% FCS. In the resulting eluates, Fc fragment was obtained 
with minor contaminants (Fig. 3.2.6 2). The purity degree of Fc fragment with 10% FCS in 
both eluates (Fig. 3.2.6 2) was 96.4%, as determined by densitometry. 
      A                                                           B 
    
Figure 3.2.6 1: SDS PAGE analysis of Fc binding to aptamer-modified sepharose (A) and sepharose 
without aptamer (B). Following samples were applied: (M) molecular weight marker, (Fc) pure Fc 
sample applied to aptamer-modified sepharose, (DL) supernatant of pure Fc after incubation with 
aptamer-modified sepharose, (W1-W5) washing fractions, and (E1-E2) eluates.  
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Figure 3.2.6 2: SDS PAGE analysis of the purification of Fc fragment from 10% FCS utilizing 
aptamer-modified sepharose. Following samples were applied: (M) molecular weight marker, (Fc + 
FCS) Fc (from 10% FCS) sample applied to aptamer-modified sepharose, (DL) supernatant of Fc (from 
10% FCS) after incubation with aptamer-modified sepharose, (W1-W5) washing fractions, and (E1-E2) 
eluates. 
Table 3.2.6 1: Characterization of aptamer functionalities immobilized on sepharose utilizing pure Fc 
fragment 
c [µM]
a
 
DApt
 b
  
[pmol/200 µl 
sepharose] 
QFc 
c 
[pmol/200 µl 
sepharose] 
EFc 
d 
[pmol/200 µl 
sepharose] 
AAFc 
e 
[%] 
EEFc 
f 
[%] 
25 536 ± 31 300.8 ± 3 291.8 ± 1 56.1 ± 7 97 ± 1 
a
 applied aptamer concentration during immobilization, 
b
 aptamer loading density on NHS-activated 
sepharose, 
c
 amount of bound Fc fragment to immobilized aptamer, 
d
 amount of eluted Fc fragment, 
e
 
aptamer activity ratio for Fc fragment  (QFc/DApt), 
f 
elution efficiency ratio for Fc fragment  (EFc/QFc). 
Table 3.2.6 1 shows 536 pmol of aptamer 264 were immobilized on 200 µL NHS-modified 
sepharose. The values of bound and eluted Fc fragment were 300 pmol and 292 pmol. The 
aptamer binding activity showed a value of 56% and the elution efficiency ratio of Fc 
fragment was 97%. Compared with aptamer 264-based purification of Fc fragment utilizing 
carboxyl-modified magnetic beads the aptamer binding activity decreased on sepharose. 
One explaination for reduced aptamer binding activity may be that the immobilized 
aptamer 264 within the pores of sepharose could not fold correctly due to the small pores, 
which led to the lower aptamer binding capability to Fc fragment. 
The functionality of aptamer-modified sepharose was further investigated by binding study 
with IgG. The SDS PAGE gel demonstrated that IgG could not bind to the immobilized 
aptamer (data not shown). It was assumed that IgG has a higher spatial demand compared 
to Fc fragment. One possible source of decreased aptamer binding activity is steric 
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hindrance of target binding which may occur when the aptamer is immobilized too close to 
the carrier surface [122]. In this case, a suitable additional spacer could be helpful for the 
binding between aptamer 264 and IgG. Spacer can either be built on the surface of 
sepharose or linked to aptamer 264 [167]. Because the coupling between NHS-activated 
sepharose and amino-modified aptamer 264 worked very well, aptamer 264 with integrated 
spacer (PEG6) was chosen for the further experiment. The immobilization and incubation 
procedures were performed the same way as that of aptamer 264 without integrated spacer. 
SDS PAGE analysis showed that IgG supplemented with 10% FCS bound to the 
immobilized aptamer 264 with integrated spacer PEG6 (Fig. 3.2.6 3). In the eluates, IgG 
was obtained with BSA contaminants and aptamer 264 fell down partially during the 
elution (at ca. 13 kDa). This effect occurred probably because part of the covalent bindings 
between aptamer 264 with integrated spacer PEG6 and NHS-modified sepharose did not 
work correctly. The purity degree of IgG in both eluates (Fig. 3.2.6 3) was 60.9%, as 
determined by densitometry. 
 
Figure 3.2.6 3: SDS PAGE analysis of the purification of IgG from 10% FCS utilizing aptamer 264 
with integrated spacer and NHS-activated sepharose. Following samples were applied: (M) molecular 
weight marker, (IgG + FCS) IgG (from 10% FCS) sample applied to aptamer-modified sepharose, (DL) 
supernatant of IgG (from 10% FCS) after incubation with aptamer-modified sepharose, (W1-W5) 
washing fractions, and (E1-E2) eluates. 
Pure IgG was utilized to characterize the binding efficiency and elution efficiency ratio by 
using aptamer 264 with integrated spacer PEG 6 (Table 3.2.6 2). The amount of 
immobilized aptamer 264 was calculated based on the Lambert–Beer equation by an 
extinction coefficient of 614 mM
-1
cm
-1
. The molecular weight of aptamer 264 with 
integrated spacer PEG 6 is 19876 Da. 
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Table 3.2.6 2: Characterization of aptamer functionalities utilizing pure IgG 
c [µM]
a
 
DApt
 b
  
[pmol/200 µL 
sepharose] 
QIgG 
c 
[pmol/200 µL 
sepharose] 
EIgG 
d 
[pmol/200 µL 
sepharose] 
AAIgG 
e 
[%] 
EEIgG 
f 
[%] 
25 771 ± 84 120.6 ± 12 15.4 ± 2 15.6 ± 21 12.8 ± 23 
a
 applied concentration of aptamer 264 with integrated spacer PEG6 during immobilization, 
b
 aptamer 
with integrated spacer loading density on NHS-activated sepharose, 
c
 amount of bound IgG to 
immobilized aptamer, 
d
 amount of eluted IgG, 
e
  aptamer activity ratio for IgG (QIgG/DApt), 
f 
elution 
efficiency ratio for IgG (EIgG/QIgG). 
Table 3.2.6 2 reports the amount of immobilized aptamer 264 with integrated spacer PEG6 
on the NHS-activated sepharose, the amount of bound and eluted IgG, the calculated 
aptamer binding activity and the elution efficiency ratio of IgG. Compared to the 
purification of Fc fragment utilizing aptamer 264 and NHS-activated sepharose, the value 
of bound IgG was one third of the bound Fc fragment. The aptamer binding activity was 
also low. This finding supported the assumption that IgG has a higher spatial demand. The 
value of elution efficiency was only 12.78%. This rather low elution efficiency could be 
explained as the pore size of sepharose is small, the IgGs, which diffused within sepharose 
particles were obstructed. A long elution process could be required. The success of using 
aptamer-modified sepharose for the purification of Fc fragment and IgG implies the 
industrial application in the future.  
The relatively poor purification results of Fc fragment and IgG by using aptamer 264-
modified sepharose could be attributed to small pore size. To diminish the influence of 
pore size, CIM
® 
monolithic columns (BIA separations, Ljubiliana, Slovenia) containing big 
internal pore size (porosity 5 µm) were used. The disc-shaped CIM
® 
DISK consists of a 
methylcarboxylate-based porous polymer matrix [129]. Especially, they can be used as a 
stationary phase for ion exchange chromatography and the purification process by using 
CIM
®
 DISK can be automated via FPLC. The immobilization of aptamer on the CIM
® 
monolithic columns was performed similarly as that of carboxyl-modified magnetic beads. 
EDC was used in the coupling process. The aptamer immobilization was induced via a 
chemical reaction, in which amino-modified aptamers were covalently coupled to EDC-
activated CIM
® 
DISK (Fig.3.2.6 4).  
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Figure 3.2.6 4: Aptamer immobilization on the methylcarboxyl-modified CIM
®
 DISK via EDC. (A) 
The methylcarboxyl-modified CIM
®
 DISK is activated via EDC. (B) The amino-modified aptamer is 
immobilized on EDC-activated CIM
®
 DISK. 
The binding study with aptamer-modified CIM
®
 monolithic columns was performed with 
pure Fc fragment. SDS PAGE analysis showed that Fc fragment was bound to the 
immobilized aptamer and was successfully eluted with 300 mM EDTA (Fig. 3.2.6 5). 
Within the first elution fraction, Fc fragment was found as a weak band, while within the 
second elution fraction Fc fragment displayed a strong and thick band. This is probably 
because that during the first elution step, the elution buffer was diluted through wash 
buffer remained in the pores of the material from the last washing step. Different from 
magnetic beads, a complete buffer exchange was hampered for the porous CIM material.  
67 
 
 
Figure 3.2.6 5: SDS PAGE analysis of Fc fragment binding to aptamer-modified CIM
®
 monolithic 
columns. Following samples were applied: (M) molecular weight marker, (FC) pure Fc fragment 
sample applied to aptamer-modified CIM
®
 monolithic columns, (DL) supernatant of pure Fc fragment 
after incubation with aptamer-modified CIM
®
 monolithic columns, (W1-W5) washing fractions, and 
(E1-E2) eluates. 
Table 3.2.6 3: Characterization of aptamer functionalities utilizing pure Fc fragment 
c [µM]
a
 
DApt
 b
 
[pmol/CIM DISK] 
QFc 
c 
[pmol/CIM DISK] 
EFc 
d 
[pmol/CIM DISK] 
AAFc 
e 
[%] 
EEFc 
f 
[%] 
25 9721.3 ± 39.8 6876.5 ± 12.9 1423.4 ± 14.1 70.7 ± 1 20.7 ± 1 
a
 applied aptamer concentration during immobilization, 
b
 aptamer loading density on CIM
®
 DISK, 
c
 
amount of bound Fc fragment to immobilized aptamer, 
d
 amount of eluted Fc fragment, 
e
 aptamer 
activity ratio for Fc fragment  (QFc/DApt), 
f 
elution efficiency ratio for Fc fragment  (EFc/QFc). 
Table 3.2.6 3 shows that 9721 pmol aptamer 264 were immobilized on the CIM monolithic 
columns and 6876 pmol Fc fragment were bound with immobilized aptamer 264, 1423 
pmol Fc fragment was eluted. The aptamer activity ratio reached 71% and the elution 
efficiency ratio was 21%. Compared with the purification method by using aptamer 264-
modified sepharose, the amount of immobilized aptamer, the amount of bound and eluted 
Fc fragment and the calculated aptamer binding activity increased significantly. The results 
supported the hypothesis that pore size interfered in the aptamer performance for sepharose. 
The relatively low elution efficiency by using CIM
®
 DISK implied an incomplete elution 
process. An extension of elution time or more elution steps could improve elution as well 
as the automatic elution process via FPLC.  
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3.3 Aptamer-based purification and depleting of small molecules 
In the previous parts, the aptamer-based purification of proteins was discussed. In this 
section, an aptamer-based purification and depleting of small molecules would be explored. 
This developed method not only trys to purify small molecules but also deplete disturbed 
components (for example, toxins). Aptamers have already been selected against small 
molecules. Several publications have reported the binding possibilities of RNA aptamers 
for theophylline [86, 168, 169]. In this study, theopylline was selected to examine the 
applicability of aptamers in the downstream processes for small molecules for the first time. 
Because malathion is unstable, a little publication has reported about malathion. However, 
malathion was investigated in this work and represented the contaminants to test the 
applicability of aptamers to deplete disturbed components for the first time too. Based on 
the binding property, aptamer-based purification of theophylline and depleting of 
malathion were examined as model systems. 
While the aptamer directed against theophylline was composed of RNA [170], an 
RNA/DNA chimera against theophylline was used in this study. Because Chavez et al. 
have reported that RNA/DNA chimera enhance the stability against degradation [171].   
According to the patent US 2008/0161236 A1.2008 [172], two given DNA aptamer 
sequences (forward and reversed) were tested. Only one of these sequences can recognize 
and bind with malathion, which was not indicated in the patent.  
3.3.1 Aptamer-based purification of theophylline 
Theophylline (C7H8N4O2, Mr = 180.2 g/mol) is used as medicinal tablet, or an injection 
preparation in the market (Euphylline®, aminophylline®, generics). It was approved in 
Switzerland in 1954. It is a white, crystalline powder, difficult to dissolve in water. It is a 
methylxanthine and it is structurally related to caffeine (Fig. 3.3.1 1). Theophylline can 
expand bronchus, can be used as antiphlogistic and diuretic tablets as well as anti-vascular 
sclerosis drug, which leads to the vascular dilatation of respiratory tracts and vasculature. 
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Figure 3.3.1 1: Schematic structure of theophylline and caffeine. 
Zimmermann et al. (2000) reported an RNA aptamer containing a 15-nt binding site 
showing high affinity and specificity for the theophylline [86]. Several RNA aptamers 
showed reduced binding affinity to their targets because of lack of divalent ions. By high-
affinity theophylline binding, divalent ions are also absolutely required. Therefore, 
removing the divalent ions and adding EDTA in the elution buffer would elute bound 
theophylline. Secondly, heating destroys the aptamers´ secondary structures. Heat 
denaturation would be investigated for the elution of small molecules. Third, it was 
reported that there was no binding of theophylline at pH 5 [173]. Therefore the pH value of 
elution buffer would be adjusted to 5 to obtain the elution of theophylline. 
In the previous sections, 20 mg/ml beads were used for the immobilization of aptamer. It 
was assumed that high beads-concentration could be probably advantagous for small 
molecules´ binding, the commercial 20 mg/ml carboxyl-modified magnetic beads were 
concentrated to 50 mg/ml. 25 µM theophylline aptamer was used and immobilized on the 
concentrated beads, as it was demonstrated by aptamer-based protein purification that an 
aptamer concentration of 25 µM resulted in best aptamer functionalities. The amount of 
immobilized aptamer was calculated based on the Lambert–Beer equation by an extinction 
coefficient of 416 mM
-1
cm
-1
. The molecular weight of theophylline aptamer is 
15710 g/mol. To determine the average amount of immobilized aptamer, three individual 
immobilization procedures were performed in parallel. All samples were measured three 
times with the help of NanoDrop. The results of three immobilization procedures are 
shown in table 3.3.1 1. The average value of 423 pmol immobilized aptamer per mg beads 
was achieved in table 3.3.1 1. 
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Table 3.3.1 1: amount of immobilized aptamers (25 µM) on carboxyl-modified magnetic beads, three 
individual immobilization procedures were performed in parallel, all resulting samples were measured 
in triplicates with Nanodrop 
 
concentration of immobilized theophylline aptamer 
on carboxyl beads (pmol/mg beads) 
immobilization 1 417 ± 7 
immobilization 2 418 ± 7 
immobilization 3 432 ± 6 
average value 423 ± 8 
 
It was reported by Zimmermann et al. (2000) that theophylline was bound to aptamer-
modified magnetic beads via heating to 65 
o
C [86]. In this experiment, binding was 
performed first by heating to 65 
o
C in the selection buffer (100 mM HEPES, 50 mM NaCl, 
5 mM MgCl2, pH 7.3) for 30 minutes at 600 rpm. After slowly cooled in room temperature, 
the binding procedure was performed for additional two hours at room temperature. 
Different elution methods were investigated to elute the bound theophylline. Divalent ions 
were removed in all elution buffers (100 mM HEPES, 50 mM NaCl, pH 7.3). First elution 
strategy was to use 100 mM EDTA in the elution buffer as the binding of theophylline to 
aptamer depended on the presence of divalent ions. EDTA removed divalent ions by 
chelating them and distroyed the correct folding of the aptamer. The second elution method 
was to use heat denaturation at 95 
o
C twice, 15 minutes each. With heat denaturation, the 
secondary structure of aptamers could be destroyed. The third elution method was to 
change pH-value from 7.3 to 5.0 in the elution buffer. Zimmermann et al. observed no 
binding of theophylline at pH 5 because of inproper aptamer folding at decreased pH value, 
at pH 5, base A7 of theophylline aptamer was protonated (Fig. 3.3.1 2) [173]. The 
quantification of theophylline was performed by company symrise (holzminden, Germany) 
and the results of theophylline binding and elution efficiency are calculated and listed in 
table 3.3.1 2. 
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Figure 3.3.1 2: Diagram of base protonation at low pH-value [173]  
Table 3.3.1 2: characterization of theophylline binding and elution efficiency ratio utilizing aptamer-                        
modified carboxyl beads under three different elution methods 
Elution 
methods 
c [µM]
a
 
DApt
 b
  
[pmol/mg 
beads] 
Qtheophylline 
c 
[pmol/mg 
beads] 
Etheophylline
d 
[pmol/mg 
beads] 
AAtheophylline 
e 
[%] 
EEtheophylline
f 
[%] 
1 (EDTA) 25 423 ± 8 0.53 0.11 0.13 20 
2 (heating) 25 423 ± 8 0.53 0.20 0.13 39 
3 (pH 5) 25 423 ± 8 0.53 0.10 0.13 19 
a
 applied aptamer concentration during immobilization, 
b
 aptamer loading density on carboxyl-
modified magnetic beads, 
c
 amount of bound theophylline to immobilized aptamer, 
d
 amount of eluted 
theophylline, 
e 
aptamer activity ratio for theopylline (Qtheophylline/DApt), 
f
 elution efficiency ratio for 
theopylline (Etheophylline/Qtheophylline). 
The results listed in table 3.3.1 2 were not ideal as the amount of bound theophylline was 
very low. Thus the binding method was optimized. Instead of cooling slowly to room 
temperature after binding at 65 
o
C, rapid cooling to room temperature was performed. 
Results showed no significant difference between slow cooling and rapid colling methods. 
Theophylline aptamer was first immobilized on concentrated carboxyl-modified magnetic 
beads (50 mg/ml). Three identical immobilization procedures were performed parallelly. 
The average amount of immobilized aptamer (applied concentraion of 25 µM) was 535 
pmol/mg beads. All three manuscripts were combined for the binding of theophylline. 
Tenfold molar excess of theophylline (48.19 µg / ml) was added into the 300 µl aptamer-
modified beads suspension.  
 
Three developed elution methods were used to test the elution efficiency of theophylline. 
Heat denaturation was retained as this method showed the best elution efficiency ratio in 
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the aforementioned experiments. A potential reason for incomplete elution of theophylline 
by heating may be that they were re-bound to aptamers. To avoid re-binding of 
theophylline, a combined elution strategy of heat denaturation and decreased pH was 
designed. The combination of using heating at 95
o
C and adjusting pH-value of 5 in the 
elution buffer was chosen as the second elution method. Urea was often used for elution 
[44]. 7 M urea was used in the elution buffer as another candidate for the elution strategy. 
The binding and elution data were provided by symrise (table 3.3.1 3) and the results of 
theophylline binding and elution efficiency are calculated and listed out in table 3.3.1 4. 
Table 3.3.1 3: theophylline binding on aptamer-modified carboxyl beads 
 theophylline [ppb] in 100 µl theophylline [pmol] in 100 µl 
Applied theophylline 61100 33.91 
Theophylline supernatant 50480 28.01 
Wash fraction 1 8004 4.44 
Wash fraction 2 1428 0.79 
Wash fraction 3 323 0.18 
Wash fraction 4 131 0.07 
Wash fraction 5 76 0.04 
Wash fraction 6 65 0.04 
E1 with elution method 1 (heating, pH 7.3) 467 0.26 
E2 with elution method 1 (heating, pH 7.3) 89 0.05 
E3 with elution method 1 (heating, pH 7.3) 20 0.01 
E1 with elution method 2 (heating, pH 5) 440 0.24 
E2 with elution method 2 (heating, pH 5) 79 0.04 
E3 with elution method 2 (heating, pH 5) 14 0.01 
E1 with elution method 3 (urea) 49 0.03 
E2 with elution method 3 (urea) 52 0.03 
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Table 3.3.1 4: characterization of theophylline binding and elution efficiency ratio on aptamer-                        
modified carboxyl beads under three different elution methods 
Elution 
methods 
c [µM]
a
 
DApt
 b
  
[pmol/mg 
beads] 
Qtheophylline 
c 
[pmol/mg 
beads] 
Etheophylline
d 
[pmol/mg 
beads] 
AAtheophylline 
e 
[%] 
EEtheophylline
f 
[%] 
95
o
C pH 7.3 25 535 0.34 0.29 0.1 85 
95
o
C pH 5 25 535 0.34 0.32 0.1 94    
urea 25 535 0.34 0.06 0.1 18 
a
 applied aptamer concentration during immobilization, 
b
 aptamer loading density on carboxyl-
modified magnetic beads, 
c 
amount of bound theophylline to immobilized aptamer, 
d
 amount of eluted 
theophylline, 
e 
aptamer activity ratio for theopylline (Qtheophylline/DApt), 
f
 elution efficiency ratio for 
theopylline (Etheophylline/Qtheophylline). 
Table 3.3.1 4 shows by using heating at a pH-value of 7.3, the elution efficiency of 
theophylline was 85%; by heating at a pH-value of 5, the elution efficiency reached the 
highest value of 94%. The high elution efficiency from both methods revealed that heating 
played a very important role in the elution process. The relatively higher elution efficiency 
at pH-value of 5 supported the hypothesis that adjusting pH-value of 5 in the elution buffer 
prevented the reversing reaction and thereby promoted the elution efficiency. Moreover, 
elution via urea showed a less efficient elution effect, less theophylline being eluted during 
the elution steps. This is probably because that 7 M urea was not efficient enough for the 
aptamer denaturation, which led to the difficulty of releasing the binding between 
theophylline and aptamer.  
Based on the successful elutions by utilizing heating and different pH-values, the 
reusability of theophylline-aptamer-beads was investigated. The elution data were provided 
by symrise (table 3.3.1 5, table 3.3.1 6). 
Table 3.3.1 5: elution data of theophylline from regenerated aptamer-modified carboxyl beads 
 theophylline [ppb] in 100 µl theophylline [pmol] in 100 µl 
Wash fraction 6 (95
o
C, pH 5) 75 0.04 
E1 (95
o
C, pH 5) 771 0.43 
E2 (95
o
C, pH 5) 119 0.07 
E3 (95
o
C, pH 5) 24 0.01 
 
The particles could be successfully reused with the elution method of heating at a pH-value 
of 5. There was even a larger amount of theophylline (176 % in comparison of the first use 
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of aptamer-modified beads with the same elution method, table 3.3.1 3) eluted from the 
reused aptamer-modified carboxyl beads. This effect can be explained that the elution was 
completed from the preceding experiment. 
Table 3.3.1 6: elution data of theophylline from regenerated aptamer-modified carboxyl beads 
 theophylline [ppb] in 100 µl theophylline [pmol] in 100 µl 
Wash fraction 6 (95
o
C, pH 7.3) 60 0,03 
E1 (95
o
C, pH 7.3) 676 0,38 
E2 (95
o
C, pH 7.3) 107 0,06 
E3 (95
o
C, pH 7.3) 14 0,01 
 
The results of the reusability via heating at a pH-value of 7.3 were similar to heating at pH 
5. A larger amount of theophylline (155 % in comparison of the first use of aptamer-
modified beads with the same elution method, table 3.3.1 3) was eluted from the reused 
aptamer-modified carboxyl beads. 
Zimmermann et al. (2000) also reported that caffeine was added to the aptamer in tenfold 
excess and the NMR spectra showed no evidence for binding [86]. There was no 
interaction between caffeine and the aptamer binding site, where theophylline could be 
specifically bound. This finding from Zimmermann emphasized that the RNA aptamer 
could discriminate the extremely closely related molecules (Fig. 3.3.1 1). 
To replicate the results of their study, three experiments were conducted. In the first 
experiment, only theophylline was incubated with aptamer-modified beads as a positive 
control. In the second experiment, eqiumolar amounts of theophylline, theobromine and 
caffeine (Fig. 3.3.1 3) were mixed and incubated with aptamer-modified beads. In the third 
experiment, theophylline, theobromine and caffeine containing 10 % coffee were mixed 
and incubated with aptamer. The binding and elution data were provided by symrise. Data 
and results are displayed in the following tables and figures. 
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Figure 3.3.1 3: Structure of theophylline, theobromine and caffeine. 
Table 3.3.1 7 shows the concentrations of theophylline in different fractions during the 
binding and elution process. Pure theophylline was applied (data provided by symrise) in 
this experiment as a positive control. The amount of eluted theophylline in the first eluate 
was 1.7 ppb, while the amount of theophylline in the last washing fraction was 0, which 
demonstrated that theophylline was successfully bound and eluted from aptamer-modified 
magnetic beads. 
Table 3.3.1 7: Purification data from pure theophylline 
 
theophylline 
[ppb] 
sample 253 
DL 207 
Wash fractions (1-7) 34.2 
Wash fraction 8 0 
Elution 1 1.7 
Elution 2 0.5 
Elution 3 0.1 
 
Table 3.3.1 8 shows no binding either between theobromine and aptamer-modified beads 
or between caffeine and aptamer-modified beads in the second experiment. Only 
theophylline was bound and successfully eluted from the mixture utilizing aptamer-
modified magnetic beads, which emphasized the aptamer´s binding specificity. The 
percentage of theophylline in the applied sample was determined to be 34%. In the elution 
theophylline was isolated with a purity of 100% (data provided by symrise). 
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Table 3.3.1 8: Purification data from mixture of theophylline, theobromine and caffeine 
 
theophylline 
[ppb] 
theobromine 
[ppb] 
caffeine 
[ppb] 
theophylline 
percentage [%] 
sample 254 228 260 34 
DL 210 195 222  
Wash fractions (1-7) 37,7 29,57 31,6  
Wash fraction 8 0,2 0 0  
Elution 1 1.6 0 0 
100 Elution 2 0.2 0 0 
Elution 3 0.1 0 0 
Fig. 3.3.1 4 graphed the results from table 3.3.1 8.  
 
Figure 3.3.1 4: Purification of theophylline from a mixture of theophylline, theobromine and caffeine 
utilizing aptamer-modified carboxyl beads. Following samples were applied: (W8) wash fraction 8 (last 
wash fraction), and (E1-E3) eluates. 
Fig. 3.3.1 4 clearly indicates that only theophylline was bound and eluted from the aptamer. 
The third experiment of purification from a mixture of theophylline, theobromine and 
caffeine containing 10 % coffee was done to simulate a complex sample. A little binding of 
theobromine and caffeine containing 10% coffee was detected in the eluates. However, 
theophylline showed the best binding and elution results. The percentage of theophylline in 
the applied sample was determined to be 26%. In the elution theophylline was isolated 
with a purity of 85%. The results are reported in table 3.3.1 9 (data provided by symrise).  
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Table 3.3.1 9: purification of theophylline from a mixture of theophylline, theobromine and caffeine 
containing 10% coffee 
 
theophylline 
[ppb] 
theobromine 
[ppb] 
caffeine 
containing 10% 
coffee 
[ppb] 
theophylline 
percentage [%] 
sample 253 215 510 26 
DL 203 182 433  
Wash fractions (1-7) 43.3 35.53 75.67  
Wash fraction 8 0,2 0 0  
Elution 1 3.1 0.06 0.5 
85 Elution 2 0.8 0 0.2 
Elution 3 0.2 0 0 
Fig. 3.3.1 5 graphed the results from table 3.3.1 9. 
 
Figure 3.3.1 5: Purification of theophylline from a mixture of theophylline, theobromine and caffeine 
containing 10% coffee utilizing aptamer-modified carboxyl beads. Following samples were applied: 
(W8) wash fraction 8 (last wash fraction) and (E1-E3) eluates. 
Figure 3.3.1 5 shows theophylline was successfully purified from the mixture. However, 
compared with the purification from the second experiment where a mixture of 
theobromine and caffeine was conducted, a little theobromine was contaminated in the first 
elution fraction and a little caffeine containing 10% coffee was contaminated in the first 
and second elution fractions. This is probably because that coffee is composed of more 
substances, like saccharides, cellulose, different acids, phenols, lignin, lipids, trigonelline 
and so forth [174]. It was assumed that some of these small substances could interfere in 
the specifical binding of aptamers. 
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3.3.2 Aptamer-based depleting of malathion 
Based on the successful purification of theophylline, the method was transfered to another 
target malathion (O, O´-dimethyl S-(1, 2-dicarbethoxyethyl) phosphorodithioate) to test the 
aptamer-based depleting of small molecules. Malathion (C10H19O6PS2, Mr = 330.4 g/mol) 
is an organophosphorus insecticide and acaricide. It is a racemate (Fig. 3.3.2 1). It is clear, 
colorless or slight yellow liquid, difficult to dissolve in water. This organophosphorus 
exhibits low mammalian toxicity. Even though the hazardous effects of malathion on 
human health and the ecosystems were already reported [175, 176], it continues to be one 
of the most utilized insecticides. In addition, malathion degrades in the environment by 
hydrolysis, photolysis, and biotransformation. It was reported that breakdown products of 
malathion are more toxic than the pesticide itself [177]. By hydrolysis at pH-value of about 
6, the half-life of malathion reduced to one or two weeks [178]. Under a condition of pH 6 
and 70 
o
C, malathion showed a half-life of 7 to 8 hours in 20% ethanol and water mixture 
[179]. In this thesis, malathion was chosen as a model system to demonstrate the 
applicability of aptamer-modified magnetic beads for the depletion of toxic compounds.  
O
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Figure 3.3.2 1: structure of malathion 
In order to find out the actual aptamer sequence which directed against malathion. Both of 
these aptamer sequences, which were indicated in patent were first immobilized on 
carboxyl-modified magnetic beads with concentrations of 50 mg/ml and 20 mg/ml. Here, 
two beads concentrations were examined to find out a suitable aptamer loading density for 
the binding of malathion. The amount of immobilized aptamer (forward) was calculated 
based on the Lambert–Beer equation by an extinction coefficient of 765 mM-1cm-1, while 
the extinction coefficient of aptamer (reversed) is 657 mM
-1
cm
-1
. The molecular weight of 
malathion aptamer is 22616 g/mol. 173.9 pmol aptamer forward and 172.9 pmol aptamer 
reversed per mg beads were bound by beads concentration of 50 mg/ml. 387.3 pmol 
aptamer forward and 379.65 pmol aptamer reversed per mg beads were bound by beads 
concentration of 20 mg/ml. The beads concentration of 50 mg/ml resulted in lower 
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malathion aptamer immobilization than the beads concentration of 20 mg/ml. Concerning 
the molecular weight of malathion is smaller as PFEI, presumably higher aptamer loading 
density could be helpful for more binding of malathion. Therefore, beads with 
concentration of 20 mg/ml were used for the binding study with malathion.  
To assess the functionalities of immobilized aptamers with forward and reversed sequences, 
the binding of malathion was performed. 10 fold excess malathion (5.48 µg/ml) of aptamer 
was added for the incubation. Binding buffer (500 mM NaCl, 10 mM Tris-HCl, 1 mM 
MgCl2, pH 7.2-7.4) was used for binding and washing. To release the bound malathion, 
three elution strategies were investigated. First, it was reported that Mg
2+
 might promote 
the aptamers´ 3D folding [130]. 100 mM EDTA was added into the elution buffer (500 
mM NaCl, 10 mM Tris-HCl, pH 7.2-7.4) as the first elution method. As already described 
for theophylline, binding of the target to the aptamer depended on the pH value, thus 
different pH values (3, 4, 9, 10) were adjusted in the elution buffer as the second elution 
method. Third, heating to 95
o
C was used to destroy the binding between aptamer and 
malathion. For this elution method, elution of malathion may not only be promoted by 
unfolding of the aptamer but also by destruction of malathion itself, which is known to be 
instable at elevated temperature [179]. 
The samples from first and third elution methods were analyzed by symrise (data not 
shown), no malathion was eluted from either aptamer forward or aptamer reversed. This is 
probably because malathion is poorly soluble in water. The chelate reaction by using 
EDTA was interfered. To solve this problem, 5% DMSO was added into the washing and 
elution buffer.  Even after the optimization, no better results were seen. Regarding to the 
heat denaturation, malathion was degraded during heating at 95
o
C as prediction. It was also 
assumed that the analysis for malathion must be done as soon as possible, as malathion is 
very unstable. Thus, the samples from the second elution method (changing pH values) 
with optimized binding and elution conditions were analyzed via HPLC in our institut. 5% 
DMSO was added in the binding and elution buffer to overcome the disadvantage of 
malathion´s poor solvability. Analysis was done directly after the downstream process. 
Via HPLC, a peak appeared from the first elution fraction by using aptamer forward at pH 
10 (Fig. 3.3.2 2). No peaks were seen by using aptamer reversed, which means that only 
the sequence of aptamer forward could bind to malathion. To determine the optimal pH 
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value for the elution of bound malathion, further three experiments were performed with 
pH values of 10, 10.5 and 11 in elution buffer. The results from HPLC showed that 
malathion could only be eluted by pH 10. Under pH values of 10.5 and 11, several peaks 
were shown in the elution fraction (data not shown), which indicated that malathion 
decomposed rapidly when using extreme pH values. 
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Figure 3.3.2 2: HPLC chromatography of different fractions originating from the aptamer-based 
capture of malathion. 
To summarize, malathion can bind with the sequence of aptamer forward and can be eluted 
at pH 10 with adding 5% DMSO in the binding and elution buffer. Malathion is unstable. It 
degraded already partly during the downstream processes, especially under extreme pH 
values or higher temperature. In the further work, it is recommended to bind and elute 
malathions in dark at 4
o
C and the analysis should be conducted as soon as possible. 
 
 
 
 
81 
 
3.4 Aptamer-based detection of proteins via quantum dots 
In addition to the application of aptamers in downstream processes, aptamers can also be 
used in the detection field. For example, aptamers are used in the field of aptasensors for 
detection of various substances [126, 127]. In this study, aptamer-based detection of 
proteins via quantum dot 525 was investigated. 
525 ITK
TM
 carboxyl-modified Quantum Dot (QD) was used. This QD was modified with 
carboxyl groups on the suface. First, aptamer 6H7 (200 µM) was immobilized on 50 µl QD 
525, resulting in immobilization of 15 aptamer per QD, while PFEI (1 mg/ml, 0.5 µl/per 
spot) as positive control and BSA (1mg/ml, 0.5 µl/per spot) as negative control were 
printed on a nitrocellulose slide. After incubation the silde printed with PFEI and BSA 
with aptamer-modified QD 525, photo of the slide under UV irradiation is shown in 
Fig.3.4 1. 
 
Figure 3.4 1: Detection of binding between aptamer and PFEI. Following samples were applied: (P) 
PFEI (positive control), (N) BSA (negative control). 
In this photo, obvious binding was seen in the row of P (positive control), but no binding 
track was seen in the row of N (negative control). This result indicated that only PFEI can 
bind with anti-his-tag aptamer (6H7). It emphasized aptamer´s binding specificity.  
In addition to PFEI, HLA was also tested for the aptamer detection capability. 1 mg/ml 
HLA (0.5 µl/per spot) was printed on the nitrocellulose slide, BSA (1mg/ml, 0.5 µl/per 
spot) was used as negative control. Different concentrations of aptamer 6H7 (50 µM, 100 
µM and 200 µM) were immobilized on QD 525 and incubated with the slide. The photo of 
slide under UV irradiation is shown in Fig. 3.4 2. 
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Figure 3.4 2: Detection of binding between aptamer and HLA. Left row: HLA (positive control), right 
row: BSA (negative control), from top to bottom: aptamer concentrations (50 µM, 100 µM, 200 µM). 
HLA was also successfully bound with aptamer 6H7. At aptamer concentration of 200 µM, 
the slide displayed a strong background, which indicated the slide needed to be washed 
more times after incubation with aptamer-modified QD to reduce the background 
interference. Also, no binding track between aptamer 6H7 and BSA was found. 
To examine if PFEI or HLA could bind directly on QDs, PFEI and HLA were printed on 
the nitrocellulose slide and incubated with QD 525 without aptamer. No binding track was 
found (data not shown). This demonstrated again the binding of his-tagged proteins were 
based on aptamer´s specifity and affinity. In the future, Fc fragment or IgG can also be 
tested against aptamer-modified QDs. Moreover, instead of printing protein manually per 
pipette on the suface of slides, slides can be coated automatically via spotters. The 
automatic coating process by using for example a noncontact spotter enables the unity and 
presiseness of slide coating and allows the characterization via GenePix®Pro 6.1. 
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4 Summary and outlook 
This study focused on the investigation of aptamer-based downstream processes for 
proteins and small molecules utilizing the recognition and binding properties of aptamers. 
The purification methods were developed on the basis of aptamer-modified magnetic beads 
and further transferred to aptamer-modified sepharose and CIM
®
 DISK for the scale-up of 
protein purification. Besides, the basic aptamer-based protein detection was investigated 
via quantum dots.  
4.1 Aptamer-based purification of his-tagged proteins 
In a previous publication, amino-modified magnetic beads were used as solid supports for 
aptamers´ immobilization and binding to their corresponding targets [36]. However, the 
amino-modified beads showed several disadvantages in the downstream processes. First, 
BSA and his-tagged protein PFEI bound unspecifically to the amino-modified surface. 
Secondly, the amino-modified surface may interact electrostatically with the phosphate 
backbone of aptamer which would result in misfolding and reduced binding activity of 
immobilized aptamer [122]. Third, toxic cyanuric chloride was required for the 
immobilization of amino-modified aptamers to the amino-modified beads. In order to 
overcome these disadvantages, an EDC-based immobilization strategy was developed in 
this study. Carboxyl-modified magnetic beads were employed for the EDC coupling 
chemistry. First, no unspecific binding of his-tagged proteins was determined on carboxyl-
modified beads. Secondly, the purity degree of PFEI reached 100% (Table 4 1), which was 
even higher than by using amino-modified magnetic beads, which was 93%, as published 
in the literature [36]. Third, the elution efficiency of PFEI utilizing aptamer 6H7 
immobilized on carboxyl-modified magnetic beads reached a high value of 97%, which 
was in accordance with that of amino-modified magnetic beads.  
His-tagged protein HLA was used to demonstrate the general applicability of the 
developed aptamer-based purification strategy. The purity degree of HLA was 85.2% 
(Table 4 1) by using aptamer 6H5 (25µM) immobilized on carboxyl-modified beads.  
To explore an automatic process, KingFisher was introduced. The automatic purification 
via KingFisher was successfully done. Results showed the automatic method was not 
suitable for the purification of proteins, which are sensible to room temperature. 
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Comparative experiments were made between aptamer-based methods and conventional 
purification methods. In this work, IMAC method for his-tagged proteins utilizing his-
select nickel magnetic agarose beads was performed. Results showed no significant 
difference. The purity degree of PFEI by using conventional IMAC method was 99%, 
while utilizing aptamer 6H5-based purification, the purity degree of PFEI reached 100% 
(Table 4 1). By the aptamer-based purification strategy, the use of toxic transition metal 
could be avoided. Thus, the aptamer-based process has potential to replace IMAC in the 
purification of proteins that should for example be used in biomedical applications. 
4.2 Aptamer-based purification of antibodies 
It was reported in a previous publication that human IgG was successfully purified from 
cell culture supernatant via an RNA aptamer and purification efficiencies equivalent to 
protein A were achieved [148]. In this study, instead of RNA aptamer, DNA aptamers 
were introduced to purify Fc fragment and IgGs by using the purification method 
developed for his-tagged proteins. The used DNA aptamers show two main advantages 
over RNA aptamers, they are more stable and cheap. The obtained purity degree was 
82.9% for Fc fragment and 97% for IgG (Table 4 1). Furthermore, elution efficiency for 
both Fc fragment and IgG reached 92% (Table 4 2). 
Comparative experiments were performed utilizing protein A. Results showed no 
significant difference. For Fc fragment, the purity degree by using aptamer 264 
immobilized on carboxyl-modified beads was 82.9%, while by using protein A was 94.7%. 
For IgG, the purity degree by using aptamer 264 immobilized on carboxyl-modified beads 
reached 97%, while by using protein A was only 79.3% (Table 4 1). Given the advantages 
of aptamers, that is, they are more easily to be produced, more stable and can be worked 
under milder conditions, aptamer-based downstream process has great potential to replace 
the conventional methods. Moreover, especially in the context of pharmaceutical antibody 
purification, the aptamers´ non-immunogenicity is advantageous as well as their cell-free 
production.  
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4.3 Scale-up 
In order to allow scale-up of aptamer-based purification strategies, the developed methods 
were transferred to sepharose 4 fast flow and CIM DISK. Compared with carboxyl-
modified beads, there was no unspecific binding by using NHS-activated sepharose. Table 
4 2 listed out the aptamers´ functionalities by using different kinds of solid supports. In 
order to compare the resultes, all values are transferred to mg immobilized aptamer or mg 
bound and eluted target per mg solid support (Table 4 2). Carboxyl-modified magnetic 
beads, however, showed the highest amount of immobilized aptamer as well as bound and 
eluted protein per mg of support. This effect may be attributed to the optimized 
downstream processes for aptamer-modified magnetic beads. 25 µM aptamer was found to 
be the optimal aptamer concentration during the immobilization for magnetic beads. This 
aptamer concentration was applied for 2 mg magnetic beads and was tested for the aptamer 
immobilization on 200 µl of sepharose and one CIM DISK. It was estimated that 200 µl 
sepharose correspond to 22.2 mg of dry sepharose, it was also weighted that one CIM 
DISK was 156.2 mg. Therefore, a higher applied aptamer concentration or a higher volume 
of applied aptamer solution could presumably enhance the aptamer loading density on 
sepharose and CIM DISK, resulting in improved binding capacity of the aptamer-modified 
material. Furthermore, the rather low aptamer activity of 56.1% for Fc fragment via 
aptamer 264-modified sepharose may be caused by the small pore size of sepharose 
interferring with the functionality of aptamer 264 (Table 4 2). This finding was confirmed 
by binding study with IgG. Because of a higher spatial demand of IgG, it could not bind 
with aptamer 264, which was immobilized on sepharose. On the contrary, Fc fragment was 
successfully purified with purity degree of 96.4% (Table 4 1) and elution efficiency of 
97% (Table 4 2). To realize the binding of IgG, a spacer of PEG6 linked to the aptamer 
was introduced. The purity degree of IgG by using aptamer with integrated spacer 
immobilized on sepharose reached 60.9% (Table 4 1).  
Based on the assumption that the small pore size of sepharose could lead to difficulties of 
aptamer functionality and result in limitations of diffusion for larger proteins, CIM
®
 DISK 
with big internal pore size was chosen as an alternative support material for the scale-up. 
Fc fragment was successfully bound and eluted via aptamer-modified CIM
®
 monolithic 
columns. The increased aptamer activity of 70.7% by using CIM DISK with big pore size 
supported the assumption (Table 4 2). 
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4.4 Aptamer-based purification and depleting of small molecules 
Several publications have reported high affinity RNA aptamers for theophylline [86, 168, 
169]. In this work, aptamer-based purification of theophylline utilizing carboxyl-modified 
magnetic beads was explored for the first time. An RNA/DNA chimera against 
theophylline was used as Chavez et al. have reported that chimera could enhance the 
stability against degradation [171]. Utilizing this RNA/DNA chimera and carboxyl-
modified beads, theophylline was suceesfully bound and eluted. The elution efficiency 
reached 94%. After succesful binding studies, the aptamer-based purification of 
theophylline from complex samples was tested. From an equimolar mixture of theophylline, 
theobromine and caffeine, theophylline was isolated with a purity degree of 100% (Table 4 
1). From a mixture of theophylline, theobromine and caffeine containing 10% coffee, 
theophylline was purified with a purity degree of 85% (Table 4 1). These experiments 
emphasized that aptamers can discriminate extremely closely related molecular compounds. 
Moreover, the aptamer-beads-matrix was successfully regenerated. In addition, malathion 
was chosen to test the possibility of depleting contaminants by using aptamers. Results 
showed that malathion could bind to corresponding DNA aptamer and be eluted at pH 10 
in the aptamer binding buffer with 5% DMSO.  
4.5 Aptamer-based detection of proteins 
Another purpose of this work was to investigate the aptamer-based protein detection. His-
tagged proteins PFEI and HLA were employed. Quantum dot 525 was introduced as 
support material. Results showed that anti-his-tag aptamers bound specifically on 
corresponding his-tagged proteins. No binding between aptamers and BSA was found. 
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Table 4 1: list of purity degrees via aptamer-based purification methods and conventional methods 
aptamer type of solid supports targets purity (%) 
6H5 carboxyl magnetic beads PFEI (from E. coli lysate) 100 
6H5 sepharose PFEI (from E. coli lysate) 97.5 
 agarose beads 
*
 PFEI (from E. coli lysate) 99 
6H5 carboxyl magnetic beads HLA (from cell-culture supernatant) 85.2 
6H5 sepharose HLA (from cell-culture supernatant)  74.1 
264 carboxyl magnetic beads Fc fragment (from 10% FCS) 82.9 
 protein A
 **
 Fc fragment (from 10% FCS) 94.7 
264 carboxyl magnetic beads IgG (from 10% FCS) 97 
 protein A
 **
 IgG (from 10% FCS) 79.3 
264 sepharose Fc fragment (from 10% FCS) 96.4 
264 + PEG 6 sepharose IgG (from 10% FCS) 60.9 
264 CIM DISK Fc fragment (from 10% FCS)  100 
theophylline 
aptamer 
carboxyl magnetic beads 
Theophylline (from a mixture with 
theobromine and caffeine 
100 
theophylline 
aptamer 
carboxyl magnetic beads 
Theophylline (from a mixture with 
theobromine and caffeine containing 
10% coffee 
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* 
comparative experiments utilizing agarose beads for the purification of his-tagged proteins via IMAC 
 ** 
comparative experiments
 
utilizing protein A-modified magnetic beads 
Table 4 2: list of aptamers´ functionalities by using different kinds of solid supports 
targets 
types of 
solid 
supports 
different 
aptamers  
c [25µM]
a
 
DApt
 b
  
[mg/mg 
beads or 
sepharose 
or disk] 
Qtarget 
c 
[mg/mg 
beads or 
sepharose 
or disk] 
Etarget 
d 
[mg/mg 
beads or 
sepharose 
or disk] 
AAtarget 
e 
[%] 
EEtarget 
f 
[%] 
PFEI 
carboxyl 
beads* 
6H5 3.11x10
-3
  6.39x10
-3
  5.85x10
-3
 86.4  91.4  
PFEI sepharose** 6H5 2.91x10
-3
 1.87x10
-3
 4.66x10
-4
 27 24.9 
Fc  
carboxyl 
beads* 
264 1.52x10
-2
 3.8x10
-2
 3.49x10
-2
 97.3 92 
Fc  sepharose** 264 4.72x10
-4
 6.77x10
-4
 6.57x10
-4
 56.1 97 
Fc 
CIM 
DISK*** 
264 1.22 x10
-3
 2.2 x10
-3
 4.56 x10
-4
 70.7 20.7 
IgG 
carboxyl 
beads* 
264 1.48x10
-2
 4.91x10
-2
 4.53x10
-2
 43.1 92.4 
IgG sepharose** 264+PEG6 6.9x10
-4
 8.15x10
-4
 1.04x10
-4
 15.6 12.8 
a
 applied different aptamers with concentration of 25 µM during immobilization, 
b
 aptamer 
immobilized on different types of solid supports, 
c
 targets bound to immobilized aptamer, 
d
 eluted 
targets, 
e
 aptamer efficiency ratio for targets (Qtarget/DApt), 
f
 elution efficiency ratio for targets 
(Etarget/Qtarget). 
* dry weight of carboxyl-modified beads was calculated via the indication provided by producer 
** dry weight of NHS-activated sepharose was estimated from a swelling factor (4-5 ml/g) of sepharose 
*** dry weight of CIM DISK was weighed without the ring 
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4.6 Outlook 
The successive aptamers´ immobilization on different kinds of solid supports developed in 
this study can be used as a versatile tool box for the purification of various proteins and 
small molecules, as well as for protein detection applications. Yet there are still many 
fields in this area to be further explored and investigated. For example, how reaction 
conditions of the aptamers´ immobilization on different surfaces can be further optimized; 
how aptamer functionalities can be increased; how the binding and elution conditions for 
the targets can be modified; how the downstream process can be simplified; how the 
automatic purification procedure can be imporved; how the operations utilizing fast protein 
liquid chromatography (FPLC) can be standardized. Furthermore, as larger proteins exhibit 
big spatial demands, suitable spacers between aptamers and surfaces of solid supports 
should be studied. Finally, aptamer-modified quantum dots for analytical applications 
should be further investigated in future work.  
This study has provided aptamer-based downstream processes for proteins and small 
molecules via various solid supports and aptamer-based protein detection via quantum dots. 
It is hoped that it will contribute to a better understanding of aptamer properties and 
functionalities and the development of more stable purification methods by using aptamers. 
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5 Appendices 
5.1 Materials 
5.1.1 Chemicals 
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid (EDC) Sigma-Aldrich, Steinheim, DE 
2-(N-morpholino) ethanesulfonic acid (MES) Sigma-Aldrich, Steinheim, DE 
Acetic acid Fluka, Buchs, CH 
Agarose Fluka, Buchs, CH 
Bovine serum albumin (BSA)                                     Sigma-Aldrich, Steinheim, DE 
Bromophenol blue Fluka, Buchs, CH 
Calcium chloride Fluka, Buchs, CH 
Cobalt sulfate   Merck, Darmstadt, DE 
Copper sulfate Merck, Darmstadt, DE 
Cyanuric chloride    Sigma-Aldrich, Steinheim, DE 
Dimethyl sulfoxide (DMSO)                                            Sigma-Aldrich, Steinheim, DE 
Disodium hydrogen phosphate   Sigma-Aldrich, Steinheim, DE 
Ethanol (95%) Merck, Darmstadt, DE 
Ethidium bromide Fluka, Buchs, CH 
Ethylenediaminetetraacetic acid (EDTA) Fluka, Buchs, CH 
Formaldehyde solution (36.5%) Fluka, Buchs, CH 
Glycerol Fluka, Buchs, CH 
Hydrochloric acid Fluka, Buchs, CH 
Imidazole Merck, Darmstadt, DE 
Magnesium chloride Fluka, Buchs, CH 
Malathion Sigma-Aldrich, Steinheim, DE 
Monosodium phosphate Merck, Darmstadt, DE 
potassium chloride Fluka, Buchs, CH 
Potassium hexacyanoferrate (III) Sigma-Aldrich, Steinheim, DE 
Rhamnose Sigma-Aldrich, Steinheim, DE 
Sodium acetate Carl Roth GmbH, Karlsruhe, DE 
Sodium bicarbonate Merck, Darmstadt, DE 
Sodium carbonate Merck, Darmstadt, DE 
Sodium chloride Fluka, Buchs, CH 
Sodium dodecyl sulfate Sigma-Aldrich, Steinheim, DE 
Sodium hydroxide Fluka, Buchs, CH 
Sulfuric acid Fluka, Buchs, CH 
Theophylline Sigma-Aldrich, Steinheim, DE 
Tris-HCl Carl Roth GmbH, Karlsruhe, DE 
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Tris-Base Carl Roth GmbH, Karlsruhe, DE 
Tween 20 Sigma-Aldrich, Steinheim, DE 
Yeast extract Fluka, Buchs, CH 
5.1.2 Buffers and solutions 
All buffer salts were purchased from Fluka (Buchs, Switzerland) and Sigma-Aldrich 
(Steinheim, Germany) and all are per analysis quality. All solutions were prepared with 
Millipore quality (MQ) water (ARIUM, Sartorius Stedim Biotech, Göttingen, Germany) 
and were filtered prior to use (Sartolab, bottle top filters, PES 0.2 µm pore size, Sartorius 
Stedim, Göttingen). The solutions for protein purification were also filtered and degassed 
in an ultrasonic bath. All used pipette tips, react-, centrifuger- and plastic-vessels were 
sterile.  
Standard buffer: 
LB-Medium  10 g/l tryptone, 10 g/l NaCl, 5 g/l yeast extract, autoclaved 
PBS 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM KH2PO4, 
pH 7.5 
TGS 25 mM Tris, 192 mM Glycin, 0,1 % SDS, pH 8.3 
equilibration buffer 
for FPLC (IMAC) 
0.1 M sodium acetate, 500 mM NaCl, pH 4.5 
binding buffer for 
FPLC (IMAC) 
50 mM NaH2PO4, 500 mM NaCl, pH 8.0 
elution buffer for 
FPLC (IMAC) 
50 mM NaH2PO4, 500 mM NaCl, 250 mM imidazole, 50% 
glycerine, pH 8.0 
Aptamer selection buffer: 
PBST-6H7 50 mM K2HPO4, 150 mM NaCl, 0.05% Tween 20, pH 7.5 
264 - 266 
20 mM Tris/HCl, 150 mM NaCl, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 
pH 7.3 
theophylline 100 mM HEPES, 50 mM NaCl, 5 mM MgCl2, pH 7.3 
malathion 500 mM NaCl, 10 mM Tris-HCl, 1 mM MgCl2, pH 7.2-7.4 
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5.1.3 Biomolecules 
5.1.3.1 Aptamers 
Aptamers 6H5 and 6H7 against his-tagged proteins were produced and modified by the 
company Biospring (Frankfurt, Germany). C6-amino-linker was attached at the 5'-end of 
the aptamer. They are 40 nt full length aptamer.  
Aptamers 264, 265 and 266 were also synthesized by the company BioSpring (Frankfurt 
am Main, DE) and 5´-modified with (C6)-NH2. Aptamers against the FC fragment of 
human IgG (264, 265, 266) were selected by Aptares (Mittelwalde, Germany) utilizing the 
MonoLex process [103]. Selection was performed in selection buffer and the library was 
composed of: 
TACGACTCACTATAGGGATCC-N21-GAATTCCCTTTAGTGAGGGTT, resulting in 
63 nt full length aptamers. Aptamer 264_5´NH2PEG6 is 65 nt full length aptamer. 
The chimera (RNA/DNA-T) against theophylline is 49 nt full length DNA/RNA. Selection 
was performed in selection buffer.  
Malathion aptamer is 72 nt full length DNA. Selection was performed in selection buffer.  
6H7 [180] GCTATGGGTGGTCTGGTTGGGATTGGCCCCGGGAGCTGGC 
6H5 [180] GGCTTCAGGTTGGTCTGGTTGGGTTTGGCTCCTGTGTACG 
264 [103] 
TACGACTCACTATAGGGATCCTTGCTTACATTACGACGTA 
CTGAATTCCCTTTAGTGAGGGTT 
265 [103] 
TACGACTCACTATAGGGATCCATAGAAAACCCCTAAACGC 
CCGAATTCCCTTTAGTGAGGGTT 
266 [103] 
TACGACTCACTATAGGGATCCTACGTCATTATGGAAACCG 
ACGAATTCCCTTTAGTGAGGGTT 
264+PEG6 
[103] 
12T ACG ACT CAC TAT AGG GAT CCT TGC TTA CAT TAC 
GAC GTA CTG AAT TCC CTT TAG TGA GGG TT 
RNA/DNA-T 
[171] 
CTCATCTGTGATCTAAGGCGAUACCAGCCGAAAGGCCCUU 
GGCAGCGUC 
Malathion 
aptamer 
forward [172] 
ATA CGG GAG CCA ACA CCA GCA GTC AAG AAG TTA AGA 
GAA AAA CAA TTG TGT ATA AGA GCA GGT GTG ACG GAT 
Malathion 
aptamer 
reversed [172] 
ATCCGTCACACCTGCTCTTATACACAATTGTTTTTCTCTTAA 
CTTCTTGACTGCTGGTGTTGGCTCCCGGTAT 
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5.1.3.2 Antibodies 
Human Fc fragment  Dianova, Hamburg, DE 
Human Immunoglobulin 1 Sigma, Traufkirchen, DE 
Human Immunoglobulin 2 Sigma, Traufkirchen, DE 
Human Immunoglobulin 3 Sigma, Traufkirchen, DE 
Human Immunoglobulin 4 Sigma, Traufkirchen, DE 
Human Immunoglobulin  Sigma, Traufkirchen, DE 
5.1.3.3 Proteins 
Pseudomonas Flurescens Esterase I (PFEI) 
Institut für Technische Chemie, 
Hannover, DE 
Human leukocyte antigen (HLA) Medical school Hannover, DE 
5.1.3.4 Other materials 
PageRuler
TM
 Unstained Protein Ladder Fermentas, St. Leon-Rot, DE 
Unstained Protein Marker 26610 Thermo Scientific Inc., Bremen, DE 
BioMag Amine-terminated magnetic beads Polysciences, Inc., Warrington, PA 
BioMag Carboxyl-terminated magnetic beads Polysciences, Inc., Warrington, PA 
BioMag Maxi Carboxyl-terminated magnetic 
beads 
Polysciences, Inc., Warrington, PA 
NHS-activated Sepharose 4 Fast Flow 
GE Healthcare Bio-Sciences AB.  
(Sweden) 
CIM
®
 DISK, Monolithic Column BIA Separations 
His-Select Nickel Magnetic Agarose Beads Sigma-Aldrich, Inc., DE 
BioMag Protein A QIAGEN, DE 
Carboxyl-modified quantum dot 525 Labeling & detection, life technologies 
5.1.3.5 Protein sequences 
Nucleotide sequence of Pseudomonas Flurescens Esterase I (PFEI) [164]: 
 
mstfvakdgt qiyfkdwgsg kpvlfshgwl ldadmweyqm eylssrgyrt iafdrpvwpl 
 
Gptldrqrlr hlrrrhrpvd rtpgpqggdp ggllhgrrrc gplhrpprqr tggrpgaagr 
 
Rhpavrpear lsagcpvdvf arfktellkd raqfisdfna pfyginkgqv vsqgvqtqtl 
 
qiallaslka tvdcvtgspk ptsartwprs typpwypwrw rlrscrsrpp akwrrs 
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5.1.4 Consumables 
Centrifugal filter units Millipore, Billerica, USA 
Falcon tubes Sarstedt, Nümbrecht, DE 
Micro titer plate Abgene, Rochester, USA 
Minisart high flow filters Sartorius, Göttingen, DE 
PLASTIBRAND pipette tips Brand, Wertheim, DE 
Slide-A-Lyzer dialysis unit mini Thermo Scientific, Waltham, USA 
Vivaspins Sartorius, Göttingen, DE 
5.1.5 Equipments 
Autoclave Systec V-150 Systec GmbH, Wettenberg, DE 
Centrifuges 
Centrifuge 5415 R 
Megafuge 1.0 RS 
Eppendorf, Hamburg, DE 
Heraeus Instruments, Osterode, DE 
FPLC BioLogic DuoFlow System BIO-RAD, München, DE 
Gel electrophoresis Thermo EC 105 Thermo Scientific, Waltham, USA 
Incubator CertomatR HK B. Braun, Melsungen, DE 
KingFisher Thermo EC Thermo Scientific, Waltham, USA 
pH meter HI 221 Calibration Check Hanna Instruments, Kehl, DE 
Plate welder ALPSTM 50 V Thermo Scientific, Waltham, USA 
Rotator-mixer Bio RS-24 Multi PeQLab Biotechnologie GmbH, DE 
Separator 6 Tube Magnetic Stand 
Applied Biosystems Deutschland 
GmbH, Darmstadt 
Shaker MTS 4 IKA, Staufen, DE 
Spectrophotometer 
Nanodrop ND-1000 
Nanodrop ND-3300 
NanoD. Techn., Wilmington, USA 
NanoD. Techn., Wilmington, USA 
Thermomixer Thermomixer comfort Eppendorf, Hamburg, DE 
Ultrasonic bath Sonorex Super RK 510 H BANDELIN, Berlin, DE 
UV desk UV-SYSTEM 
INTAS Science Imaging Instruments 
GmbH, Göttingen, DE 
Water Purification 
System 
Arium 611 Sartorius, Göttingen, DE 
PI measuring Fluoroskan Ascent Thermo Electron Corporation, DE 
Spectrophotometer Multiskan Spectrum Thermo Electron Corporation, DE 
5.1.6 Software 
SkanIt RE for MSS 2.1 Thermo Electron Corporation, DE 
Ascent software for Fluoroskan Ascent Thermo Electron Corporation, DE 
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KingFisher Thermo Scientific, Waltham, USA 
NanoDrop ND-1000 NanoD. Techn., Wilmington, USA 
NanoPlotter NPC16 GeSiM, Großerkmannsdorf, DE 
5.2 Methods 
In the following sections, the methods frequently used in this study will be described. 
Subsequently, the optimized protocols of this thesis will be discussed chronologically. 
5.2.1 General methods 
5.2.1.1 Determination of concentrations of immobilized aptamers as well as bound and 
eluted proteins via NanoDrop
TM 
 
Concentrations of aptamers and proteins can be determined with a NanoDrop
TM 
1000 
spectrophotometer (Thermo Scientific, Waltham, MA) by using the respective buffer as 
blank. For fluorescently labbeled aptamers and proteins, NanoDrop
TM
 3000 
spectrophotometer can be utilized. To determine the average concentration value, all 
samples were measured 3 times. 
The aptamer concentration can be determined via NanoDrop
TM
 1000 by measuring the 
absorbance at λ = 260 nm. The concentrations were calculated based on the Lambert-Beer 
equation utilizing the respective extinction coefficients. Accordingly, following relation 
between the absorbance A and concentration C exists: 
C = 
d
A

                                                               (Formula 5.2.1.1: Lambert-Beer Law ) 
C : aptamer concentration in µmol/l 
A:  absorbance by λ= 260 nm 
ε:   molar decadic extinction coefficients ε in (mM-1cm-1) – (provided by Biospring) 
d:   the layer thickness in cm (d= 1 cm) 
With the help of NanoDrop ND 1000, the concentration of protein can be determined by 
measuring the absorbance at λ = 280 nm utilizing the Beer-Lambert law (formula 5.2.1.1). 
Accordingly, following relation between the absorbance A and concentration C exists: 
95 
 
C = 
d
A

                                                            (Formula 5.2.1.1: Lambert-Beer Law) 
C:  protein concentration in µmol/l 
A:  absorbance by λ= 280 nm 
ε:   molar decadic extinction coefficients ε in (mM-1cm-1) – (calculated by online   
      protein extinction coefficient calculator – BioMol.Net) 
d:   the layer thickness in cm ( d= 1 cm) 
5.2.1.2 Determination of concentrations of immobilized aptamers via propidium iodide 
(PI) assay 
Concentrations of aptamers can also be determined via PI assay. Per experiment, 25 µl 
solution of PI (0.1 mg/ml diluted in 0.9% NaCl) were added into 100 µl of sample solution 
(max. 5 µM DNA, as the calibration curve is no longer linear for DNA concentraions of 5-
10 uM). After thoroughly mixing, the mixture was incubated in the dark for 30 minutes at 
room temperature. Measurements could be conducted in the fluoroskan ascent device with 
Abs/Em = 536/617 nm. 
5.2.1.3 Determination of concentrations of bound and eluted proteins via Bradford assay 
Concentrations of proteins can also be determined via Bradford protein assay [163] 
utilizing coommassie-Blue in a 96well Plate. Bovine serum albumin (BSA) was selected as 
standard protein for generating a calibration curve. This BSA standard curve is linear over 
a short range, from 0 µg/ml to 200 µg/ml, the linearity is lost if the concentration is over 
200 µg/ml. Thus it is necessary to dilute samples within the range before analysis. 
Concentrations of samples were calculated from absorbance values utilizing the formula of 
corresponding linear equations. Instead of using BSA, pure target protein can also be used 
as standard assay, in this study, pure IgG was also used as standard protein for the 
determination of IgG concentrations in the complex sample. First, BSA solutions (2 mg/ml 
in 0.9% NaCl solution) or pure IgG solutions were diluted in corresponding buffer to reach 
the concentrations of 0 µg/ml, 20 µg/ml, 40 µg/ml, 100 µg/ml, 150 µg/ml, and 200 µg/ml. 
Secondly, all samples for analysis were diluted in the range between 0 and 200 µg/ml. 
Third, 250 µl Bradford reagent were added to corresponding BSA (50 µl) and protein (50 
µl) samples simultaneously. Afterwards, they were thoroughly mixed so that the 
developing colour was homogeneous. All samples were then pipetted into a 96-well plate. 
96 
 
After 15 minutes incubation at room temperature, the measurement of the absorbance was 
carried out at 595 nm by using multiskan spectrum device. Based on these measured values, 
a calibration curve can be obtained and taking into account the dilution factor used to 
calculate the protein concentration of the sample. 
5.2.1.4 Determination of the amount of immobilized aptamers 
To calculate the amount of aptamer in each fraction, the sample volume was required 
(Formula 5.2.1.4 A). The amount of immobilized aptamer was calculated via subtraction of 
the amount of the aptamer remaining in solution after immobilization (including the 
aptamer found in the washing fractions) from the amount of aptamer in the original 
solution (formula 5.2.1.4 B). 
Aptamer  mol = C 





L
mol
* V  L *10-3    
Formula 5.2.1.4 A: Calculation the amount of aptamer in each fraction (µmol) 
 
immobilized Aptamer  mol = Aptamer (applied)  mol -Aptamer (DL)  mol -Aptamer 
(Wash 1)  mol -Aptamer (Wash 2)  mol -Aptamer (Wash 3)  mol -Aptamer (Wash 4)  mol … 
Formula 5.2.1.4 B: Calculation the amount of immobilized Aptamer (µmol) 
5.2.1.5 Determination of the amount of bound and eluted proteins 
The same formulas were used to calculate the amount of bound and eluted protein in each 
fraction, taking into account the measured sample volume, the amount of bound protein 
was calculated via subtraction of the amount of the protein remaining in solution after 
incubation (including the protein found in the washing fractions) from the amount of 
protein in the original solution. Because imidazole disturbs the results adsorbtion at 280 
nm determined by NanoDrop, eluates were first treated with dialysis (see 5.2.1.8) against 
the selection buffer. The amount of eluted protein was calculated via addition of the 
amount of the protein which was found in the elution fractions. 
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5.2.1.6 Calculation of aptamer activity 
The aptamer activity was defined as the proportion of the immobilized aptamer that was 
able to bind the target. The activity can be calculated as the percentage of the amount of 
bound protein divided by immobilized aptamer on the solid supports according to formula 
5.2.1.6.  
Aptamer activity (%) = 
 
 molaptamerdimmobilize
molproteinbound


 * 100%  
Formula 5.2.1.6: Calculation of aptamer activity (%) 
5.2.1.7 Calculation of the elution efficiency 
The elution efficient is the percentage of the amount of eluted protein divided by bound 
protein. The elution efficiency can be calculated according to formula 5.2.1.7. 
Elution efficiency (%) = 
 
 molproteinbound
molproteineluted


 * 100%  
Formula 5.2.1.7: Calculation of elution efficiency (%) 
5.2.1.8 Dialysis 
Slide-A-Lyzer mini dialysis units were used for the dialysis. Because imidazole interfers 
with the determination of protein concentration by using NanoDrop
TM
 1000, it is necessary 
to remove imidazole in the eluates via dialysis. Protein eluates contaminated with 
imidazole were pipetted into the dialysis units and incubated overnight in the 
corresponding aptamer selection buffer at 4
o
C. 
5.2.1.9   Buffer exchange by ultrafiltration 
The proteins originally dissolved in PBS buffer were rebuffered via ultrafiltration in the 
aptamer selection buffer. The ultrafiltration is based on the separation of proteins by using 
a membrane filter. Here, the membrane filter should have a defined pore size, which is 
smaller as the molecular weight of corresponding protein. Protein solution was added into 
the membrane filter. Higher molecular weight components, which are larger than the pore 
size of membrane, remained in the retentate after centrifugation. 
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300 µl solution of protein was concentrated to 100 µl via centrifugation at 13,000 rpm and 
4
o
C for 2 minutes. Afterwards, 200 µl selection buffer was added into the concentrated 
protein solution and the centrifugation was repeated. After six times of rebuffering, the 
concentration of protein was set to 1 mg/ml in the selection buffer. 
5.2.1.10 SDS-PAGE 
 SDS-running buffer: 25 mM Tris, 192 mM Glycin, 0,1% SDS; pH 8,3 (1 x TGS) 
 SDS-sample buffer: 20 mM Tris/HCl, 2 mM EDTA (Na-salt), 5% SDS, 0,02% 
            Bromophenol blue in 90 ml H2O, directly before use, 10% 2- Mercaptoethanol  
            and 10% Glycerin (55%) were added to the sample buffer. 
      Table 5.2.1.10: Composition of separation gel (A) and stacking gel (B). 
      A                                                                             B 
component 12% 16%  component 6% 
Polyacylamide/Bisacrylamide
-mixture (37.5:1), 40% 
 4.5 ml 6 ml  
Polyacylamide/Bisacrylamide
-mixture (37.5:1), 40% 
750 µl 
SDS (1%) 1.5 ml 1.5 ml  SDS (1%) 300 µl 
Tris/HCl (1.5 M), pH 8.8 4.2 ml 4.2 ml  Tris/HCl (1.5 M), pH 6.8 630 µl 
ddH2O 4.8 ml 3.3 ml  ddH2O 3700 µl 
TEMED 30 µl 30 µl  TEMED 10 µl 
APS (25%) 30 µl 30 µl  APS (25%) 10 µl 
 
The components of the separation gel were mixed and the solution was pipetted into the 
SDS-PAGE apparatus. After the polymerization of the separation gel (ca. 20 min.), the 
stacking gel was poured into the apparatus, after 20 minutes, the stacking gel was 
polymerized. 
The protein samples were mixed 1:1 with the SDS-sample buffer and then heated for 
10 minutes at 95°C. Subsequently, 10 µl of the samples and 3.5 µl of the protein-Ladder 
(Unstained Protein Ladder) were applied to the gel. 
The separation was carried out first at 100 V. After the samples passed through the 
stacking gel, the running voltage was changed to 150 V. As soon as the bromphenol blue 
runned on of the bottom of the gel, the electrophoresis was stopped. 
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Silver staining 
 Fixer: 500 ml H2O, 500 ml EtOH, 100 ml acetic acid 
 Farmers reducer: 0.1% potassium hexacyanoferrat (III) und 0.1% sodium 
thiosulfate 
 2.5% sodium carbonate solution 
 5% acetic acid 
 0.1% silver nitrate solution 
 
The silver staining of the gel was performed on a shaker. First, the gel was incubated in 
fixer for 30 minutes at room temperature and 300 rpm. After two short washing steps with 
ultrapure water, the gel was incubated in 100 ml Farmers reducer solution for 2.5 min at 
room temperature and 300 rpm. Subsequently, the gel was washed with ultrapure water for 
three times, 10 minutes each and then incubated in 0.1% silver nitrate solution for 30 min 
at room temperature and 300 rpm. The gel was then washed with ultrapure water twice, 30 
second each and rinsed with 2.5% sodium carbonate solution. To have a band development, 
the gel was incubated in 100 ml of 2.5% sodium carbonate solution with 400 µl 
formaldehyde solution (36.5%). To stop staining, the gel was put into the 5% acetic acid 
solution for 10 minutes. Afterwards, it was stored in ddH2O. 
5.2.2 Production of the target protein PFEI 
5.2.2.1 His-Tag-Protein PFEI 
His-tagged protein PFEI was produced from E. coli cells and purified by FPLC. The 
extraction and purification of the protein PFEI is described below. 
5.2.2.1.1 Cultivation 
For the preparation of pre-culture, 40 ml of LB-medium, 200 µl E. coli from frozen culture 
and 120 µl 25 mg/ml ampicillin derived solution were added into a 100 ml shake flask. The 
culture was incubated overnight in the shaker at 37
o
C and 150 rpm. 
For the main-culture, 100 ml of LB-medium, 200 µl ampicillin solution (25 mg/ml) and 1 
ml of the preculture were added into 500 ml shake flasks, respectively. The culture was 
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incubated in the shaker for 2-4 hours at 37
 o
C and 150 rpm. At an OD600-value of 0.8-1.0, 1 
ml rhamnose (0.2 g/ml) was added for the induction of PFEI-his. The cultures were 
incubated for further 4 h in the shaker at 37
 o
C and 150 rpm. 
5.2.2.1.2 Cell harvest and disruption  
The cultures were transferred into 50 ml centrifuge tubes and centrifuged with 4000 g for 
15 minutes at 4
o
C. The supernatant was discarded as PFEI is expressed intracellularly. The 
cell pellets were then resuspended in 2-4 ml of 1 x PBS buffer and disrupted via 
ultrasonication for three times, one minute each (90 W, 0.6 sec pulse duration) under ice 
cooling. The cell constituents were centrifuged and the supernatant was selected. The 
successful expression was determined by SDS-PAGE analysis. 
5.2.2.1.3 Purification via FPLC 
 equilibration buffer: 0.1 M sodium acetate, 0.5 M NaCl, pH 4.5 
 metal salt solutions: 0.1 M cobaltchloride (CoCl2*6H2O) in equilibration 
buffer, pH 4.5 
 binding buffer: 50 mM NaH2PO4, 0.5 M NaCl, pH 8.0 
 elution buffer: 0.1 M sodium acetate, 0.5 M NaCl, 0.1 M imidazole, 50% 
glycerol, pH 4.5 
The implementation of the PFEI purification via FPLC is described below. Sartobind 
IDA 75 module was used as the membrane adsorber. All buffers and lysates were sterile 
filtered before. All buffers were degassed in an ultrasonic bath before use. The 
purification was carried out with a flow rate of 1 ml / min, and was monitored with a flow 
detector at 280 nm. 
 The membrane adsorber was flushed with 10 ml of equilibration buffer. 
 Subsequently, the membrane was loaded with 10 ml of 0.1 M cobaltchloride 
salt solution. 
 Excess metal salt was washed away with 20 ml equilibration buffer. 
 The membrane was rinsed with 20 ml binding buffer. 
 The protein-containing sample was diluted in the binding buffer and passed 
             through the adsorber. 
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 PFEI was eluted with 20 ml elution buffer. 
 For membrane regeneration, the membrane was washed with 10 ml 
equilibration buffer and the metal ions were removed with 10 ml of 1 M 
sulfuric acid. 
 The membrane was washed with 20 ml equilibration buffer and was stored in 
equilibration buffer supplemented with 0.02% sodium azide. 
The success of the purification was monitored via SDS-PAGE analysis. 
5.2.3 Immobilization of aptamers on different solid supports 
The coupling of aptamers and the subsequent washing steps of all the following 
experiments were performed in eppendorf tubes (except for CIM
®
 DISK, which was 
performed in the 6-well-plate) under rotation of 20 rpm by utilizing a rotator (Shaker 
Rotator Bio-RS-24, Peqlab, Erlangen, Germany). Magnetic separations were performed 
manually by using a magnetic separator (6 Tube Magnetic Stand, Applied Biosystems 
Deutschland GmbH, Darmstadt).  
5.2.3.1 Immobilization of aptamers on magnetic beads 
As an alternative to columns, magnetic nanoparticles were developed for a quick and easy 
extraction of biomolecules. The immobilization of aptamers on two types of magnetic 
beads is described below. 
5.2.3.1.1 Immobilization of aptamers on amino-modified magnetic beads 
To achieve the covalent binding between amino-modified aptamers and amino-modified 
magnetic beads, either the amino-linker from aptamer or the amino-groups on the surface 
of magnetic beads need to be activated. First, the amino-modified aptamers were activated 
via cyanuric chloride.  
 Aptamer activation via cyanuric chloride 
Aptamer 6H7 (5´-GCT ATG GGT GGT CTG GTT GGG ATT GGC CCC GGG 
AGC TGG C-3´) was diluted in ddH2O to adjust the concentration to 220 µM. 
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100 µl aptamer 6H7 (220 µM) was further diluted in 100 µL 0.2 M sodium borate 
buffer (1.2366 g Boric acid in 100 ml ddH2O, pH 8.4) to get an aptamer 
concentration of 110 µM – the concentration was determined with the help of 
NanoDrop ND 1000 [1:100 diluted in 0.1 M sodium borate buffer (0.6183 g Boric 
acid in 100 ml ddH2O, pH 8.4)].  
22 µl freshly prepared cyanuric chloride solution (9.2 mg cyanuric chloride diluted 
in 10 ml acetonitrile) were added into 100 µl aptamer 6H7 (110 µM) solution and 
incubated for one hour at room temperature. 
Excess of cyanuric chloride was removed by buffer exchange with in 0.1 M sodium 
borate buffer for 6 times by using vivaspins with 3 kDa membrane – the 
concentration was determined again with the help of NanoDrop ND 1000 (1:100 
diluted in 0.1 M sodium borate buffer). 
 Immobilization of activated aptamer on the amino-modified magnetic beads 
100 µl of the amino-modified magnetic particle suspension (20 mg/ml) were 
washed with 100 µl 0.1 M sodium borate buffer (pH 8.4) twice, 15 minutes each. 
100 µl activated aptamer 6H7 solution diluted in 0.1 sodium borate buffer (pH 8.4) 
to achieve three different aptamer concentrations (25 µM, 45 µM and 85 µM), 
these three aptamer 6H7 solutions were added into the washed magnetic beads and 
incubated with them for 2 hours at room temperature. To remove unbound aptamer, 
the aptamer-modified magnetic beads were washed with 100 µl of 0.1 M sodium 
borate buffer (pH 8.4) for three times, 15 minutes each. Finally, the aptamer 6H7 
modified-magnetic beads were washed with selection buffer (50 mM K2HPO4, 150 
mM NaCl, 0.05% Tween 20, pH 7.5) for 15 minutes, transferred to fresh SB and 
stored at 4°C. 
5.2.3.1.2 Capping of amino-modified magnetic beads 
Because PFEI can bind directly on the amino-modified magnetic beads, comparatively not 
directly on the carboxyl-modified magnetic beads, amino surface was modified via 
succinic anhydride (capping) before binding with aptamer. 
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Per capping, 100 µl amino-modified magnetic beads suspension (20 mg/ml) was collected 
via magnetic separator. 100 µl succinic anhydride solutions [0.138 g succinic anhydride + 
8.5 ml dimethyl sulfoxide (DMSO) + 0.5 ml 0.1 M sodium bicarbonate, pH 9.4] were 
added to the collected beads and incubated with them for 5 minutes at room temperature. 
Afterwards, the beads were washed with 100 µl ddH2O for three times, one minute each at 
room temperature. Finally, the beads were further washed with 100 µl 25 mM MES buffer 
[2-(N-morpholino) ethanesulfonic acid, pH 6.0] twice, 10 minutes each at room 
temperature. After capping, the amino groups were transferred to carboxyl groups. In order 
to immobilize amino-modified aptamers onto capped magnetic beads, an EDC-mediated 
coupling was used. 
5.2.3.1.3 Immobilization of aptamers on carboxyl-modified magnetic beads 
Two binding processes for the aptamer immobilization on carboxyl-modified magnetic 
beads were tested. 
First, the two steps coating process was performed. Thereby 100 µL of carboxyl-modfied 
magnetic beads suspension (20 mg/ml) was washed with 100 µl 25 mM MES buffer (pH 6) 
twice, 10 minutes each at room temperature. A freshly prepared mixture of 16.7 µl solution 
of NHS and 16.7 µl solution of EDC (50 mg/ml in ice cold 25 mM MES buffer, pH 6) was 
added into the washed beads and incubated with them for 30 minutes at room remperature. 
After incubation, the beads were washed with 100 µl 25 mM MES buffer (pH 6) twice, 10 
minutes each. Afterwards, 100 µl of 100 µM amino-modified aptamer 6H7 in 25 mM MES 
(pH 6) were added into the activated beads and incubated for one hour at room temperature. 
In order to remove the unbound aptamers, the aptamer-beads mixture was washed with 100 
µl 50 mM Tris buffer (pH 7.4) for four times, 15 minutes each at room temperature. 
Consequently, the coated beads were resuspended to 100 µl selection buffer (PBST-6H7) 
and stored at 2-8 
o
C.  
By one step coating procedure, 100 µl of the carboxyl-modified magnetic particle 
suspension (20 mg/ml) were washed with 100 µl 25 mM MES (pH 6) twice, 10 min each. 
Afterwards 100 µl of 25 µM (for some experiment, different concentrations of aptamers 
were applied) aptamer solution in MES (pH 6) was added into washed beads and incubated 
with them for 30 minutes at room temperature. EDC solution (10 mg/ml) was freshly 
prepared in ice cold MES (pH 6) and 30 µl of this solution were added to the aptamer and 
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magnetic beads suspension. The coupling was performed at 4°C overnight. To remove 
unbound aptamer, the aptamer-modified magnetic beads were washed with 100 µl of 50 
mM Tris buffer (pH 7.4) for four times, 10 minutes each. Finally, the magnetic beads were 
washed with selection buffer (SB, pH 7.5) for 30 minutes, transferred to fresh SB and 
stored at 4°C. 
5.2.3.2 Immobilization of aptamers on NHS-modified sepharose 
200 µl NHS-modified sepharose suspension were pipetted into a 2 ml eppendorf tubes, the 
sepharose particles were washed with 1 ml ice cold HCl (1 mM ) for four times, 10 
minutes each at 4
o
C and 20 rpm. After each washing fraction, particles were settled down 
for 20 minutes and 900 µl supernatant were removed. 200 µl aptamer (diluted in standard 
buffer: 25 µM in 0.2 M NaHCO3, 0.5 M NaCl, pH 8.3) were added into the washed 
sepharose particles. After incubation over night at 4
o
C, the aptamer-modified sepharose 
was then blocked with 1 ml Tris buffer (50 mM, pH 7.4) for 8 times, 15 minutes each at 
4
o
C. Consequently, to fold the immobilized aptamer, the aptamer-modified sepharose was 
washed with 1 ml aptamer selection buffer (20 mM Tris, 150 mM NaCl, 4 mM KCl, 1 mM 
MgCl2, 1 mM CaCl2, pH7.3) twice, 15 minutes each at 4
o
C. After washing, the aptamer-
modified sepharose was stored in SB at 4
o
C. 
5.2.3.3 Immobilization of aptamers on methyl-carboxyl-modified CIM® DISK 
The washing and incubation process of CIM
®
 DISK was performed in a 6 well-plate. The 
CIM
®
 DISK was washed first with 1 ml MES buffer (25 mM, pH 6) twice, 30 min each at 
room temperature. Afterwards, 1 ml of 25 µM aptamer was added into the washed CIM
®
 
DISK and incubated with it for 30 minutes at roomtemperature. After incubation, 300 µl 
ice-cold freshly prepared EDC (10 mg/ml in MES buffer) were added into the solution. 
The reaction was further performed over night at 4
o
C and 300 rpm. In order to remove 
unbound aptamer, the aptamer-modified CIM
®
 DISK was washed with 1 ml Tris buffer (50 
mM, pH 7.4) for four times, 15 minutes each at 4
o
C. Consequently, the aptamer-modified 
CIM
®
 DISK was washed with 1 ml aptamer selection buffer for 15 minutes at 4
o
C. 
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5.2.4 Aptamer-based downstream process for his-tagged proteins 
5.2.4.1 Aptamer-based purification of PFEI 
The self produced PFEI was first rebuffered into the aptamer selection buffer (50 mM 
K2HPO4, 150 mM NaCl, 0.05% Tween 20, pH 7.5), in which the aptamers were selected. 
The rebuffering process was performed in a VIVASPIN 500 membrane (10,000 
MWCOPES). Afterwards, the rebuffered PFEI was diluted to a concentration of 1 mg/ml. 
100 µL of PFEI (1 mg/ml) was then added to and incubated with aptamer-modified-matrix 
for four hours at 4
o
C. To remove unbound and unspecifically bound PFEI, the aptamer-
modified matrix bound with PFEI was washed with 100 µL of wash buffer 1 (SB + 350 
mM NaCl, pH 7.5) for 10 minutes at 4
o
C, and then washed with wash buffer 2 (SB + 350 
mM NaCl + 1 M KCl, pH 7.5) for another 10 minutes at 4
o
C, and one time more with wash 
buffer 1 for 30 minutes at 4
o
C. Afterwards, PFEI was eluted with elution buffer (SB + 1M 
imidazole, pH 7.5) twice (30 min. + 10 min.) at 4
o
C. Finally, the aptamer-modified matrix 
was transferred to fresh SB and stored at 4
o
C. 
5.2.4.2 Aptamer-based purification of HLA 
His-tagged protein HLA was first rebuffered into the selection buffer (50 mM K2HPO4, 
150 mM NaCl, 0.05% Tween 20, pH 7.5), in which the aptamers were selected. The 
rebuffering process was performed in a VIVASPIN 500 membrane (10,000 MWCOPES). 
The concentration of rebuffered HLA was set to 1 mg/ml. 100 µL of HLA (1 mg/ml) was 
then added to and incubated with aptamer-modified-matrix for four hours at 4
o
C. To 
remove unbound and unspecifically bound HLA, the aptamer-modified matrix bound with 
HLA was washed with 100 µL of selection buffer for three times (2x10 min., 1x30 min.) at 
4
o
C and 20 rpm. Subsequently, HLA was eluted with elution buffer (SB + 1M imidazole, 
pH 7.5) twice (30 min. + 10 min.) at 4
o
C. Finally, the aptamer-modified matrix was 
transferred to fresh SB and stored at 4
o
C. 
5.2.4.3 Aptamer-based automatic downstream process via KingFisher 
KingFisher was used to achieve the automatic aptamer-based downstream process. First, 
the automatic procedure was programmed with the help of KingFischer software. All 
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samples and buffers were pipetted into the 96-well-plate. The automatic process is 
described below: 
1) 100 µl of with MES buffer (25 mM, pH 6.0) washed carboxyl-beads – collect beads 
2) 100 µl aptamer (diluted in MES) + 30 µl EDC (in 25 µM ice-cold MES), 2 hours 
incubation, slowly – collect beads 
3) 100 µl Tris (50 mM, pH 7.4), 15 minutes washing, slowly – collect beads 
4) 100 µl Tris (50 mM, pH 7.4), 15 minutes washing, slowly – collect beads 
5) 100 µl Tris (50 mM, pH 7.4), 15 minutes washing, slowly – collect beads 
6) 100 µl Tris (50 mM, pH 7.4), 15 minutes washing, slowly – collect beads 
7) 100 µl PBST-6H7 buffer (pH 7.5), 30 minutes washing, slowly – collect beads 
8) 100 µl PBST-6H7 buffer – regenation 
The finished samples were stored at 4
o
C. 
5.2.5 Aptamer-based downstream process for antibodies 
The commercial Fc fragment and IgG were first rebuffered into the SB (20 mM Tris, 150 
mM NaCl, 4 mM KCl, 1 mM MgCl2, 1 mM CaCl2, pH 7.3), in which the aptamers were 
selected. The rebuffering process was performed utilizing a 10 kDa centrifugal membrane. 
Afterwards, the Fc fragment and IgG were diluted to a concentration of 1 mg/ml. 100 µl 
(except for CIM
®
 DISK was 1 ml) each of these samples was then added and incubated 
with aptamer-modified matrix for four hours at 4
o
C. To remove unbound and 
unspecifically bound Fc fragment and IgG, the aptamer-modified matrix bound with Fc 
fragment or IgG was washed with 100 µl (for sepharose and CIM
®
 DISK were 1 ml) of 
wash buffer 1 (SB + 500 mM KCl, pH 7.3) for 20 minutes at 4
o
C, and then washed with 
SB (pH 7.3) for two times more, 20 minutes each at 4
o
C. Afterwards, the Fc fragment or 
IgG was eluted with elution buffer (20 mM Tris, 300 mM EDTA, pH 7.3) twice, 30 
minutes each at 4
o
C. Finally, the aptamer-modified matrix was transferred to fresh SB and 
stored at 4
o
C. 
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5.2.6 Aptamer-based downstream process for small molecules 
5.2.6.1 Aptamer-based purification of theophylline 
20 mg/ml carboxyl-modified magnetic particle suspension was concentrated to 50 mg/ml. 
Three identical experiments were done in parallel. Per experiment, 100 µl of the magnetic 
particle suspension (50 mg/ml) was washed with 100 µl MES buffer (25 mM, pH 6) twice, 
10 minutes each. Afterwards 100 µl of 25 µM theophylline aptamer solution in MES (pH 6) 
was added and incubated for 30 minutes at room temperature. EDC solution (10 mg/ml) 
was prepared in ice-cold MES buffer (pH 6) immediately before 30 µl of this solution was 
added to the aptamer and magnetic beads suspension. The coupling was performed at 4°C 
overnight. To remove unbound aptamer, the aptamer-modified magnetic beads were 
washed with 100 µl of 50 mM Tris buffer (pH 7.4) for four-times, 15 minutes each and 
washed further with theophylline binding buffer (100 mM HEPES, 50 mM NaCl, 5 mM 
MgCl2, pH 7.3) for 30 minutes at 4°C, Finally, the aptamer-modified magnetic beads were 
transferred to fresh theophylline binding buffer and stored at 4°C. 
All aptamer-modified magnetic beads resulting from the three experiments were combined. 
10-fold excess of theophylline was added and incubated with 300 µl aptamer-modified 
magnetic particle suspension for 30 minutes at 65
o
C and 600 rpm. During the incubation, 
the suspension was resuspended every 5 minutes. Afterwards, the suspension was cooled to 
20
o
C. The temperature dropped ca. 5
o
C in every 3 minutes, while the suspension was 
resuspended every 3 minutes. The theophylline-aptamer-beads suspension was incubated 
for further 2 hours at room temperature. After incubation, the suspension was washed with 
theophylline binding buffer for 6 times, 15 minutes each. Consenquently, the bound 
theophylline was eluted via different elution methods.  
First, theophylline was eluted with elution buffer 1 (100 mM HEPES, 100 mM EDTA, 50 
mM NaCl, pH 7.3) for two times (1x30 min. and 1x15 min.). Secondly, theophylline was 
eluted via heating at 95
o
C in elution buffer 2 (100 mM HEPES, 50 mM NaCl, pH 7.3) 
twice, 15 minutes each. During the heating, the suspension was resuspended in every 5 
minutes. Third, theophylline was eluted via heating at 95
o
C in elution buffer 3 (100 mM 
HEPES, 50 mM NaCl, pH 5) for two times (1x30 min. and 1x15 min.). Last, theophylline 
was eluted with elution buffer 4 (100 mM HEPES, 7 M urea, 50 mM NaCl, pH 7.3) for 
twice, 15 minutes each. 
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5.2.6.2 Aptamer-based purification of malathion 
100 µl of the carboxyl-modified magnetic particle suspension (20 mg/ml and 50 mg/ml) 
were washed with 100 µl MES buffer (25 mM, pH 6) twice, 10 minutes each. Afterwards 
100 µl of 25 µM malathion aptamer (forward and reversed) solution in MES (pH 6) was 
added and incubated for 30 minutes at room temperature. EDC solution (10 mg/ml) was 
prepared in ice-cold MES buffer (pH 6) immediately before 30 µl of this solution was 
added to the aptamer and magnetic beads suspension. The coupling was performed at 4°C 
overnight. To remove unbound aptamer, the aptamer-modified magnetic beads were 
washed with 100 µl of 50 mM Tris buffer (pH 7.4) for four times, 15 minutes each. Finally, 
the apamer-modified magnetic beads were washed with malathion binding buffer (500 mM 
NaCl, 10 mM Tris-HCl, 1 mM MgCl2, pH 7.2-7.4) for 30 minutes at 4°C and transferred to 
fresh malathion binding buffer and stored at 4°C. 
Malathion can be purified via aptamer-modified magnetic beads. Before incubation with 
malathion, the aptamer-modified magnetic beads were first heated at 95
o
C for 5 minutes. 
After heating, the aptamer-beads matrix was incubated with SB for 5 hours at 4
o
C. 10-fold 
excess malathion (5.48 µg/ml) of aptamer was added and incubated with the aptamer-
modified beads over night at 4
o
C. The malathion aptamer-modified beads were then 
washed with malathion binding buffer (500 mM NaCl, 10 mM Tris-HCl, 1 mM MgCl2, pH 
7.2-7.4) for three times (2x10 min. and 1x30 min.) at 4
o
C. Consenquently, malathion was 
eluted with binding buffer under different pH-values (binding buffer, pH 3, 4, 9, 10). 
5.2.7 Conventional purification methods 
5.2.7.1 Purification of lysate (PFEI) via his-select nickel magnetic agarose beads 
PFEI containing E. coli lysate was first rebuffered into 1xPBS buffer, the rebuffered PFEI 
was diluted in a buffer of PBST-6H7 + 20 mM imidazole to a concentration of 1 mg/ml. 
100 µl of prepared PFEI (1 mg/ml) were added and incubated with 100 µl his-select nickel 
magnetic agarose beads for 4 hours and 20 rpm at 4
o
C. After incubation, the nickel 
magnetic agarose beads were washed with 1 ml wash buffer (50 mM sodium phosphate, 
pH 8.0, 0.3 M sodium chloride, 10 mM imidazole) for three times, 10 minutes each at 4
o
C 
and 20 rpm. Consequently, PFEI was eluted with 500 µl elution buffer (50 mM sodium 
phosphate, pH 8.0, 0.3 M sodium chloride, 250 mM imidazole) for 15 minutes at 4
o
C. 
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5.2.7.2 Purification of antibodies via BioMag® Protein A 
100 µl BioMag
®
 Protein A particles were pipetted into a 1.5 ml microcentrifuge tube. The 
BioMag particles were washed with 750 µl protein A buffer (0.1 M Tris-HCl, 0.15 M NaCl, 
pH 7.5) for three times, 10 minutes each. After washing, 50 µl of 1 mg/ml Fc fragment and 
10% FCS or 50 µl of 1 mg/ml IgG and 10% FCS were diluted in 50 µl protein A buffer 
and added to the BioMag particles and then incubated for 1 hour at room temperature. 
During the incubation, the tube was vortexed every 5 minutes. Afterwards, the BioMag 
particles were washed with 750 µl protein A buffer for three times, 15 minutes each. 50 µl 
glycine (0.1 M) was added, the pH-value was adjusted to 2.5. The tube was vortexed and 
incubated for 5 minutes at room temperature. Consequently, 2.5 µl NaOH (1 M) was added 
to the eluted fraction. 
5.2.8 Aptamer-based detection of proteins via quantum dots 
5.2.8.1 Immobilization of aptamers on ITK carboxyl-modified quantum dots  
50 µl of 8 µM carboxyl-modified quantum dots 525 were washed with 200 µl MES buffer 
(100 mM, pH 6.0) via 10 kDa MWCO centrifugal membrane with 4000 g for 2.5 minutes 
at room temperature. The volume was concentrated from 250 ul to 50 µl. The washed 
quantum dots were diluted with MES to 400 µl and transfered into an eppendorf tube. 196 
µl quantum dots were transferred into another eppendorf tube, 49 µl aptamer solutions 
(300 µM) were added and incubated with 196 µl quantum dots for 30 minutes at room 
temperature. After incubation, 9.8 µl ice-cold freshly prepared EDC (5.75 mg/ml in MES) 
were added to the solution. The reaction was performed over night at 4
o
C and 20 rpm. 
After immobilization of aptamers to quantum dots, 100 µl aptamer-modified quantum dots 
were pipetted into a 100 kDa MWCO centrifugal membrane. 400 µl Tris buffer (50 mM 
Tris, pH 7.4) were added into the centrifugal membrane. The solution was centrifuged with 
4000 g and this washing step was repeated 6 times, 2.5 minutes each at 4
o
C. 400 µl flow-
throughs from each washing fraction were stored in eppendorf tubes at 4
o
C for the 
quantification. After 6 times washing, the supernatant was diluted with Tris buffer to 200 
µl. 100 µl of this solution were dialysed in PBST-6H7 at 4
o
C overnight. 
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5.2.8.2 Detection of proteins via aptamer-modified quantum dots 
After diaysis, volume of the remaining solution was measured via pipettes. The 
concentration of aptamer-modified quantum dots (19220.23 pmol aptamer were 
immobilized to 76.9 µl 8 µM QD 525) was determinated via NanoDropTM 3000. 40 µl 
solutions were selected and diluted with 760 µl PBST-6H7 buffer. 
0.5 µl PFEI (1 mg/ml) (or HLA, 1 mg/ml) and 0.5 µl BSA (1 mg/ml, as negative control) 
were pipetted on a nitrocellulose silde. The silde was then incubated for 30 minutes at 
room temperature. Afterwards, the silde surface was blocked with 2% milk powder (in 
PBS buffer) for 45 minutes at room temperature. The slide was then washed with PBST-
6H7 buffer for three times, 5 minutes each at room temperature. 800 µl aptamer-modified 
quantum dots solutions were incubated with the slide via an adhesive film in a plastic box 
over night at room temperature under light exclusion. After incubation, the slide was 
washed with PBST-6H7 in the dark for 3 times, 10 minutes each. Consequently, the slide 
was dried under a stream of nitrogen. The slide was detected under a UV light (312 nm).  
5.3 Abbreviations 
µM: µmol/L 
3D: Three dimentional 
ADP: 
AMP: 
APS: 
Adenosine diphosphate 
Adenosine monophosphate 
Ammonium persulfate 
ATP: 
AVP: 
BSA: 
Adenosine triphosphate 
Arginine-vasopressin 
Bovine Serum Albumin 
CEC: Capillary Electro Chromatography 
CHO: Chinese Hamster Ovary 
ddH2O: Didistilled water 
DMSO: Dimethyl Sulfoxide 
DNA: Deoxyribonucleic acid 
EC: Efficiency ration 
EDC: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimid 
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EDTA: Ethylenediaminetetraacetic acid 
ELISA: 
FCS: 
Enzyme-linked immuno sorbent assay 
Fetal Calf Serum 
FMN: Flavin Mononucleotide 
FPLC: Fast Protein Liquid Chromatography 
HCV: Hepatitis C Virus 
HLA: Human Leukocyte Antigen 
HPLC: High-pressure Liquid Chromatography 
IgG: Immunoglobulin G 
kDa: Kilodalton 
LC: Liquid Chromatography 
MHH: Medical School Hannover 
MES: 2-(N-Morpholino)ethanesulfonic acid 
NAD: 
NHS: 
Nicotinamide adenine dinucleotide 
N-Hydroxysuccinimide 
NMR: Nuclear Magnetic Resonance 
PBS: Phosphate Buffered Saline 
PCR: Polymerase Chain Reaction 
PEG: Polyethylene glycol 
PFEI: Pseudomonas Flurescens Esterase 
PI: Isoelectric Point 
PI: Propidium Iodide 
QD: Quantum Dot 
RNA: Ribonucleic acid 
rpm: rounds per minute 
RT-PCR: Real Time - Polymerase Chain Reaction 
SB: Selection Buffer 
SDS: Sodium Dodecyl Sulfate 
SDS PAGE: Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
SELEX: Systematic Evolution of Ligands by Exponential enrichment 
TEMED: Tetramethylethylenediamine 
Tris: Tris(hydroxymethyl)aminomethane 
UV: Ultraviolet 
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